

Supplementary Materials

**Combining Photoredox Catalysis and Hydrogen Atom Transfer for
Dearomative Functionalization of Electron Rich Heteroarenes**

Peng Ji,¹ Xiang Meng,¹ Jing Chen,¹ Feng Gao,¹ Hang Xu,¹ and Wei Wang^{1,2,3*}

¹*Department of Pharmacology and Toxicology, R. Ken Coit College of Pharmacy*

²*Chemistry and Biochemistry, and ³University of Arizona Cancer Center*

University of Arizona, Tucson, AZ 85721-0207, USA

Table of Contents


| | |
|---|------|
| 1. General Information..... | S2 |
| 2. General Procedures and Optimization of Reaction Conditions | S2 |
| 3. Measurement of redox potential | S9 |
| 4. Compounds Characterization Data | S11 |
| 5. Spectral Data..... | S50 |
| 6. Single crystal X-ray diffraction data of 30 | S171 |
| 7. References | S177 |

1. General Information

All commercially available reagents were purchased from Sigma Aldrich, Ark Pharm Inc., Matrix Chemical, Combi-Blocks, AKSci, Alfa Aesar, Acros, Ambeed or TCI America, and used as received unless otherwise noted. Merck 60 silica gel was used for chromatography, and Whatman silica gel plates with a fluorescence F254 indicator were used for thin-layer chromatography (TLC) analysis. ^1H and ^{13}C NMR spectra were recorded on Bruker Avance 500 MHz or Varian 400 MHz. Chemical shifts in ^1H NMR spectra are reported in parts per million (ppm) relative to residual chloroform (7.26 ppm) or dimethyl sulfoxide (2.50 ppm) as internal standards. ^1H NMR data are reported as follows: chemical shift (δ ppm), multiplicity (s = singlet, d = doublet, quint = quintet, sext = sextet, m = multiplet, br = broad), coupling constant in Hertz (Hz) and hydrogen numbers based on integration intensities. ^{13}C NMR chemical shifts are reported in ppm relative to the central peak of CDCl_3 (77.16 ppm) or DMSO-d_6 (39.52 ppm) as internal standards. High-resolution mass spectrometry was performed in Analytical and Biological Mass Spectrometry Center. Both blue LED strip and 40 W Kessil Blue LEDs were purchased from Amazon. Cyclic voltammetry was performed at 25 °C on a CH Instrument CHI604xD electrochemical analyzer using a glassy carbon working electrode, a platinum wire counter electrode, and the Ag/AgCl reference electrode calibrated using ferrocene redox couple (4.8 V below vacuum). HPLC analyses with chiral stationary phase were carried out using a SHIMADZU HPLC system with SPD-20A detector. Samples are purified by flash column chromatography on Teledyne ISCO CombiFlash NextGen300+.


2. General Procedures and Optimization of Reaction Conditions

2.1 General procedure A (3-34)




To an oven-dried 20 mL-Schlenk tube equipped with a stir bar, was added nucleophiles (0.2 mmol), arenes (0.3 mmol), PhSeH (0.04 mmol), **Mes-Acr-4** (0.005 mmol), 2,6-lutidine (0.04 mmol) as the base, will be added. The tube was evacuated and back-filled with N_2 for three times, then sealed with rubber stopper and parafilm. Subsequently, the degassed dichloromethane (4 mL) was added. The reaction was irradiated by the two 40 W Kessil Blue LEDs, cooling by the electronic fan (Figure S1). After the completion of reactions, the resulted solution was purified by flash column chromatography on silica gel eluting with hexane/ethyl acetate or DCM/ethyl acetate in the indicated ratio.

2.2 General procedure B (36-73)




To an oven-dried 20 mL-Schlenk tube equipped with a stir bar, was added azoles (0.24 mmol), indole (0.2 mmol), PhSeH (0.04 mmol), **Mes-Acr-4** (0.005 mmol), 2,6-lutidine (0.04 mmol) as the base, will be added. The tube was evacuated and back-filled with N₂ for three times, then sealed with rubber stopper and parafilm. Subsequently, the degassed dichloromethane (4 mL) was added. The reaction was irradiated by the two 40 W Kessil Blue LEDs, cooling by the electronic fan (Figure S1). After the completion of reactions, the resulted solution was purified by flash column chromatography on silica gel eluting with hexane/ethyl acetate or DCM/ethyl acetate in the indicated ratio.

2.3 General procedure C (74-71, 88-91)




To an oven-dried 20 mL-Schlenk tube equipped with a stir bar, was added amine or P(OEt)₃ (0.4 mmol), indole (0.2 mmol), PhSeH (0.04 mmol), **Mes-Acr-4** (0.005 mmol), 2,6-lutidine (0.04 mmol) as the base, will be added. The tube was evacuated and back-filled with N₂ for three times, then sealed with rubber stopper and parafilm. Subsequently, the degassed dichloromethane (4 mL) was added. The reaction was irradiated by the two 40 W Kessil Blue LEDs, cooling by the electronic fan (Figure S1). After the completion of reactions, the resulted solution was purified by flash column chromatography on silica gel eluting with hexane/ethyl acetate or DCM/ethyl acetate in the indicated ratio.

2.4 General procedure D (78-87)




To an oven-dried 20 mL-Schlenk tube equipped with a stir bar, was added carboxylic acids (0.6 mmol) or acetic acid (5.0 equiv), indole (0.2 mmol), PhSeH (0.04 mmol), **Mes-Acr-4** (0.005 mmol), 2,6-lutidine (0.04 mmol) as the base, will be added. The tube was evacuated and back-filled with N₂ for three times, then sealed with rubber stopper and parafilm. Subsequently, the degassed dichloromethane (4 mL) was added. The reaction was irradiated by the two 40 W Kessil Blue LEDs, cooling by the electronic fan (Figure S1). After the completion of reactions, the resulted solution was purified by flash column chromatography on silica gel eluting with hexane/ethyl acetate or DCM/ethyl acetate in the indicated ratio.

2.5 General procedure E (85-87)




To an oven-dried 20 mL-Schlenk tube equipped with a stir bar, was added indole (0.2 mmol), PhSeH (0.04 mmol), **Mes-Acr-4** (0.005 mmol), TMSCN (0.4 mmol). The tube was evacuated and back-filled with N₂ for three times, then sealed with rubber stopper and parafilm. Subsequently, the degassed MeOH or EtOH (4 mL) was added. The reaction was irradiated by the two 40 W Kessil Blue LEDs for 48 hours, cooling by the electronic fan (Figure S1). After the completion of reactions, the resulted solution was purified by flash column chromatography on silica gel eluting with hexane/ethyl acetate or DCM/ethyl acetate in the indicated ratio.

2.6 Intramolecular reaction



To an oven-dried 20 mL-Schlenk tube equipped with a stir bar, was added indole acid (0.2 mmol), PhSeH (0.04 mmol), **Mes-Acr-4** (0.005 mmol), 2,6-lutidine (0.04 mmol). The tube was evacuated and back-filled with N₂ for three times, then sealed with rubber stopper and parafilm. Subsequently, the degassed DCM (4 mL) was added. The reaction was irradiated by the two 40 W Kessil Blue LEDs for 48 hours, cooling by the electronic fan (Figure S1). After the completion of reactions, the resulted solution was purified by flash column chromatography on silica gel eluting with hexane/ethyl acetate or DCM/ethyl acetate in the indicated ratio.

2.7 Large scale synthesis 36



To an oven-dried 20 mL-Schlenk tube equipped with a stir bar, was added pyrazole (349 mg, 5.13 mmol) (5.0 equiv), indole (1.1 g, 4.28 mmol), PhSeH (91 uL, 0.86 mmol), **Mes-Acr-4** (61 mg, 0.11 mmol), 2,6-lutidine (66 uL, 0.11 mmol) as the base, will be added. The tube was evacuated and back-filled with N₂ for three times, then sealed with rubber stopper and parafilm. Subsequently, the degassed dichloromethane (4 mL) was added. The reaction was irradiated by the two 40 W Kessil Blue LEDs, cooling by the electronic fan. After the completion of reactions, the resulted solution was purified by flash column chromatography on silica gel eluting with hexane/ethyl acetate (5:1) in the indicated ratio.






Figure S1. Reaction setup

2.8 reaction conditions optimization


Table S1. Optimization of different photocatalyst.




| PC (2.5 mol%) | Base (0.2 equiv) | HAT cat (0.2 equiv) | Solvent | Con (M) | Yield | Z/E |
|---------------|------------------|---------------------|---------|---------|-------|-----|
| Mes-Acr2 | 2,6-lutidine | PhSeH | DCM | 0.05 | 42 | 1:1 |
| Mes-Acr4 | 2,6-lutidine | PhSeH | DCM | 0.05 | 81 | 1:1 |
| Mes-Acr3 | 2,6-lutidine | PhSeH | DCM | 0.05 | 58 | 1:1 |

| | | | | | | |
|-----------------|--------------|-------|-----|-------------|--------------|------------|
| Mes-Acr1 | 2,6-lutidine | PhSeH | DCM | 0.05 | 50 | 1:1 |
| 4CzIPN | 2,6-lutidine | PhSeH | DCM | 0.05 | trace | - |
| DCA | 2,6-lutidine | PhSeH | DCM | 0.05 | trace | - |
| TPT | 2,6-lutidine | PhSeH | DCM | 0.05 | trace | - |


Table S2. Optimization of HAT agents



| PC (2.5 mol%) | Base (0.2 equiv) | HAT cat (0.2 equiv) | Solvent | Con (M) | Yield | E/Z |
|----------------------|-------------------------|----------------------------|----------------|----------------|--------------|------------|
| Mes-Acr4 | 2,6-lutidine | PhSeH | DCM | 0.05 | 81 | 1:1 |
| Mes-Acr4 | 2,6-lutidine | Ph ₃ SiSH | DCM | 0.05 | 60 | 2:1 |
| Mes-Acr4 | 2,6-lutidine | iPr ₃ SiSH | DCM | 0.05 | 57 | 1.2:1 |
| Mes-Acr4 | 2,6-lutidine | PhSH | DCM | 0.05 | 56 | 2.7:1 |
| Mes-Acr4 | 2,6-lutidine | TRIPSH | DCM | 0.05 | 54 | 1:1 |
| Mes-Acr4 | 2,6-lutidine | 4-NO ₂ PhSH | DCM | 0.05 | 38 | 6.6:1 |
| Mes-Acr4 | 2,6-lutidine | 4-MeOPhSH | DCM | 0.05 | 63 | 1:1 |
| Mes-Acr4 | 2,6-lutidine | Cysteine | DCM | 0.05 | 55 | 1.6:1 |
| Mes-Acr4 | 2,6-lutidine | 3,6-diCl-1,2-PhSH | DCM | 0.05 | 53 | 1.2:1 |
| Mes-Acr4 | 2,6-lutidine | 2-NH ₂ PhSe | DCM | 0.05 | 33 | 2.9:1 |
| Mes-Acr4 | 2,6-lutidine | SHCH ₂ COOMe | DCM | 0.05 | 56 | 2.7:1 |
| Mes-Acr4 | 2,6-lutidine | Adman-SH | DCM | 0.05 | 63 | 1:1 |
| Mes-Acr4 | 2,6-lutidine | PhCOSH | DCM | 0.05 | 56 | 2.1:1 |

Table S3. Optimization of Solvent.

| PC (2.5 mol%) | Base (0.2 equiv) | HAT cat (0.2 equiv) | Solvent | Con (M) | Yield |
|---------------|------------------|---------------------|-------------------|---------|-------|
| Mes-Acr4 | 2,6-lutidine | PhSeH | DCE | 0.05 | 63 |
| Mes-Acr4 | 2,6-lutidine | PhSeH | DMF | 0.05 | trace |
| Mes-Acr4 | 2,6-lutidine | PhSeH | ACN | 0.05 | 16 |
| Mes-Acr4 | 2,6-lutidine | PhSeH | PhCF ₃ | 0.05 | 57 |

Table S4. Optimization of concentration and control studies.

| PC (2.5 mol%) | Base (0.2 equiv) | HAT cat (0.2 eq) | Solvent | Con (M) | Yield | E/Z |
|---------------|------------------|------------------|---------|---------|-------|----------|
| Mes-Acr4 | 2,6-lutidine | PhSeH | DCM | 0.05 | 81 | 1:1 |
| Mes-Acr4 | 2,6-lutidine | PhSeH | DCM | 0.1 | 60 | 3:1 |
| Mes-Acr4 | 2,6-lutidine | PhSeH | DCM | 0.2 | 30 | 2:1 |
| Mes-Acr4 | none | PhSeH | DCM | 0.05 | 68 | 1:1.4 |
| Mes-Acr4 | 2,6-lutidine | none | DCM | 0.05 | 23 | 1:1 |
| Mes-Acr4 | 2,6-lutidine | PhSeH | DCM | 0.05 | trace | No light |
| Mes-Acr4 | 2,6-lutidine | PhSeH | DCM | 0.05 | trace | No PC |

3. Measurement of redox potential

Procedure for measurement of the redox potential:

Voltammetric measurements were recorded on a CH Instruments: Model 600E Series Electrochemical Analyzer using a standard three electrodes setup in dry and degassed MeCN (10 mL), with ferrocene as an internal reference ($E^{0}_{1/2} = + 0.40$ V vs SCE) and $n\text{Bu}_4\text{NPF}_6$ as the electrolyte (0.10 mmol). Cyclic voltammograms were recorded at a scan rate of 0.2 V/s.




Figure S2. Redox potential of indole.




Figure S3. Redox potential of furan.




Figure S4. Redox potential of 2-methoxythiophene.





Figure S5. Redox potential of 2,5-dimethoxythiophene.


4. Compounds Characterization Data



O-methyl (E)-4-(1H-pyrazol-1-yl)but-3-enethioate (3): The title compound was prepared according to the general procedure A. The crude residue was purified by column chromatography on silica gel with an eluent of hexanes/ethyl acetate (2:1) to furnish the pure compound as a yellow oil in 76% yield.

¹H NMR (400 MHz, CDCl₃) δ 7.60 (d, *J* = 1.8 Hz, 1H), 7.58 (d, *J* = 2.4 Hz, 1H), 6.94 (dt, *J* = 14.1, 1.4 Hz, 1H), 6.34 (t, *J* = 2.1 Hz, 1H), 6.25 (dt, *J* = 14.1, 7.6 Hz, 1H), 4.10 (s, 3H), 3.59 (dd, *J* = 7.6, 1.4 Hz, 2H).

¹³C NMR (101 MHz, CDCl₃) δ 220.61, 140.85, 129.41, 127.56, 111.38, 107.00, 59.29, 46.68.




O-methyl (Z)-4-(1H-pyrazol-1-yl)but-3-enethioate (3):

¹H NMR (400 MHz, CDCl₃) δ 7.62 (d, *J* = 1.8 Hz, 1H), 7.56 (d, *J* = 2.6 Hz, 1H), 6.85 (dt, *J* = 9.4, 1.9 Hz, 1H), 6.33 (t, *J* = 2.1 Hz, 1H), 5.61 (dt, *J* = 9.4, 7.1 Hz, 1H), 4.12 (s, 3H), 4.09 (dd, *J* = 7.1, 1.8 Hz, 2H).

¹³C NMR (101 MHz, CDCl₃) δ 221.55, 140.95, 130.53, 126.56, 113.79, 106.46, 59.32, 44.10.


HRMS (ESI) *m/z* [M + H]⁺ calculated for C₈H₁₀N₂OS: 183.0587, found 183.0585.



O-methyl (Z)-4-(4-iodo-1H-pyrazol-1-yl)but-3-enethioate (4): The title compound was prepared according to the general procedure A. The crude residue was purified by column chromatography on silica gel with an eluent of hexanes/ethyl acetate (2:1) to furnish the pure compound as a yellow oil in 76% yield.

¹H NMR (500 MHz, CDCl₃) δ 7.611 (s, 1H), 7.607 (s, 1H), 6.792 (dd, *J* = 9.3, 2.0 Hz, 1H), 5.647 (dt, *J* = 9.5, 7.2 Hz, 1H), 4.114 (s, 3H), 4.008 (dd, *J* = 7.2, 1.8 Hz, 2H).

¹³C NMR (126 MHz, CDCl₃) δ 219.35, 145.80, 134.67, 125.97, 115.21, 59.36, 43.90, 29.55.




O-methyl (E)-4-(4-iodo-1H-pyrazol-1-yl)but-3-enethioate (4):

$^1\text{H NMR}$ (500 MHz, CDCl_3) δ 7.65 (s, 2H), 7.58 (s, 1H), 6.88 (d, $J = 14.1$ Hz, 1H), 6.23 (dt, $J = 14.1, 7.6$ Hz, 2H), 4.10 (s, 3H), 3.57 (dd, $J = 7.5, 1.4$ Hz, 4H).

$^{13}\text{C NMR}$ (126 MHz, CDCl_3) δ 220.09, 145.64, 131.78, 128.80, 112.51, 59.29, 46.31, 29.70.


HRMS (ESI) m/z $[\text{M} + \text{H}]^+$ calculated for $\text{C}_8\text{H}_9\text{IN}_2\text{OS}$: 308.9553, found 308.9552.



***O*-methyl (*Z*)-4-(4-bromo-1*H*-pyrazol-1-yl)but-3-enethioate (5):**

$^1\text{H NMR}$ (500 MHz, CDCl_3) δ 7.59 (s, 1H), 7.57 (s, 1H), 6.77 (dt, $J = 9.4, 1.9$ Hz, 1H), 5.66 (dt, $J = 9.3, 7.2$ Hz, 1H), 4.11 (s, 3H), 4.00 (dd, $J = 7.2, 1.8$ Hz, 2H).

$^{13}\text{C NMR}$ (126 MHz, CDCl_3) δ 220.82, 141.37, 130.31, 126.16, 115.21, 59.39, 43.84, 29.85.




***O*-methyl (*E*)-4-(4-bromo-1*H*-pyrazol-1-yl)but-3-enethioate (5):**

$^1\text{H NMR}$ (500 MHz, CDCl_3) δ 7.63 (s, 1H), 7.54 (s, 1H), 6.97 – 6.71 (m, 1H), 6.22 (dt, $J = 14.6, 7.6$ Hz, 1H), 4.10 (s, 3H), 3.57 (dd, $J = 7.6, 1.4$ Hz, 2H).

$^{13}\text{C NMR}$ (126 MHz, CDCl_3) δ 220.23, 141.38, 129.16, 127.54, 112.53, 59.46, 46.43, 29.85.


HRMS (ESI) m/z $[\text{M} + \text{H}]^+$ calculated for $\text{C}_8\text{H}_9\text{BrN}_2\text{OS}$: 260.9692, found 260.9690.



***O*-methyl (*Z*)-4-(4-chloro-1*H*-pyrazol-1-yl)but-3-enethioate (6):**

$^1\text{H NMR}$ (500 MHz, CDCl_3) δ 7.57 (s, 1H), 7.53 (s, 1H), 6.74 (d, $J = 9.3$ Hz, 1H), 5.66 (dt, $J = 9.3, 7.2$ Hz, 1H), 4.11 (s, 3H), 4.00 (dd, $J = 7.2, 1.8$ Hz, 2H).

$^{13}\text{C NMR}$ (126 MHz, CDCl_3) δ 220.84, 139.31, 128.10, 126.26, 115.11, 59.39, 43.83, 33.28.




***O*-methyl (*E*)-4-(4-chloro-1*H*-pyrazol-1-yl)but-3-enethioate (6):**

^1H NMR (500 MHz, CDCl_3) δ 7.60 (s, 1H), 7.51 (s, 1H), 6.84 (d, $J = 14.2$ Hz, 1H), 6.20 (dt, $J = 14.1, 7.6$ Hz, 1H), 4.10 (s, 4H), 3.56 (dd, $J = 7.6, 1.4$ Hz, 3H).

^{13}C NMR (126 MHz, CDCl_3) δ 220.25, 139.33, 129.31, 125.28, 112.40, 59.45, 46.43, 31.07.


HRMS (ESI) m/z $[\text{M} + \text{H}]^+$ calculated for $\text{C}_8\text{H}_9\text{ClN}_2\text{OS}$: 217.0197, found 217.0194.



***O*-methyl (*Z*)-4-(4-fluoro-1*H*-pyrazol-1-yl)but-3-enethioate (7):**

^1H NMR (500 MHz, CDCl_3) δ 7.48 (d, $J = 4.7$ Hz, 1H), 7.47 (d, $J = 3.8$ Hz, 1H), 6.69 (dt, $J = 9.4, 1.9$ Hz, 1H), 5.63 (dt, $J = 9.4, 7.2$ Hz, 1H), 4.11 (s, 3H), 3.99 (dd, $J = 7.2, 1.8$ Hz, 2H).

^{13}C NMR (126 MHz, CDCl_3) δ 220.95, 150.26 (d, $J = 248.2$ Hz), 128.38 (d, $J = 13.8$ Hz), 126.74, 116.17 (d, $J = 27.9$ Hz), 114.49, 59.36, 43.79.




***O*-methyl (*E*)-4-(4-fluoro-1*H*-pyrazol-1-yl)but-3-enethioate (7):**

^1H NMR (500 MHz, CDCl_3) δ 7.50 (d, $J = 4.7$ Hz, 1H), 7.44 (d, $J = 4.1$ Hz, 1H), 6.81 (dd, $J = 14.3, 1.3$ Hz, 1H), 6.11 (dt, $J = 14.2, 7.5$ Hz, 1H), 4.10 (s, 3H), 3.56 (dd, $J = 7.5, 1.4$ Hz, 2H).

^{13}C NMR (126 MHz, CDCl_3) δ 220.40, 150.67 (d, $J = 249.2$ Hz), 130.05, 128.38 (d, $J = 13.8$ Hz), 113.17 (d, $J = 28.1$ Hz), 111.52, 59.44, 46.43.


HRMS (ESI) m/z $[\text{M} + \text{H}]^+$ calculated for $\text{C}_8\text{H}_9\text{ClN}_2\text{OS}$: 217.0197, found 217.0194.



***O*-methyl (*Z*)-4-(4-methyl-1*H*-pyrazol-1-yl)but-3-enethioate (8):**

^1H NMR (500 MHz, CDCl_3) δ 7.42 (s, 1H), 7.32 (t, $J = 0.9$ Hz, 1H), 6.76 (dt, $J = 9.4, 1.8$ Hz, 1H), 5.51 (dt, $J = 9.4, 7.1$ Hz, 1H), 4.11 (s, 3H), 4.06 (dd, $J = 7.2, 1.8$ Hz, 2H), 2.12 – 1.91 (m, 3H).

^{13}C NMR (126 MHz, CDCl_3) δ 221.73, 141.70, 129.06, 126.61, 112.48, 59.29, 44.11, 31.06, 8.86.




***O*-methyl (*E*)-4-(4-methyl-1*H*-pyrazol-1-yl)but-3-enethioate (8):**

^1H NMR (500 MHz, CDCl_3) δ 7.40 (s, 2H), 7.38 – 7.36 (m, 2H), 6.87 (d, $J = 14.2$ Hz, 1H), 6.11 (dt, $J = 14.2, 7.6$ Hz, 2H), 4.09 (s, 6H), 3.56 (dd, $J = 7.5, 1.4$ Hz, 4H), 2.08 (s, 6H).

^{13}C NMR (126 MHz, CDCl_3) δ 221.03, 141.69, 129.74, 126.09, 110.16, 59.40, 46.85, 29.84, 8.98.


HRMS (ESI) m/z $[\text{M} + \text{H}]^+$ calculated for $\text{C}_9\text{H}_{12}\text{N}_2\text{OS}$: 197.0743, found 197.0743.



Ethyl (*Z*)-1-(4-methoxy-4-thioxobut-1-en-1-yl)-1*H*-pyrazole-4-carboxylate (9):

^1H NMR (500 MHz, CDCl_3) δ 7.99 (d, $J = 14.3$ Hz, 2H), 6.80 (dt, $J = 9.4, 1.9$ Hz, 1H), 5.77 (dt, $J = 9.4, 7.1$ Hz, 1H), 4.29 (q, $J = 7.1$ Hz, 2H), 4.10 (s, 3H), 4.03 (dd, $J = 7.1, 1.9$ Hz, 2H), 1.34 (t, $J = 7.1$ Hz, 3H).

^{13}C NMR (126 MHz, CDCl_3) δ 220.62, 162.77, 142.01, 133.47, 125.88, 116.80, 115.83, 60.51, 59.33, 43.79, 14.47.




Ethyl (*E*)-1-(4-methoxy-4-thioxobut-1-en-1-yl)-1*H*-pyrazole-4-carboxylate (9):

^1H NMR (500 MHz, CDCl_3) δ 8.04 (s, 1H), 7.97 (s, 1H), 6.89 (dt, $J = 14.0, 1.5$ Hz, 1H), 6.39 (dt, $J = 14.1, 7.5$ Hz, 1H), 4.30 (q, $J = 7.1$ Hz, 2H), 4.10 (s, 3H), 3.59 (dd, $J = 7.6, 1.4$ Hz, 2H), 1.34 (t, $J = 7.1$ Hz, 3H).

^{13}C NMR (126 MHz, CDCl_3) δ 219.88, 162.73, 142.13, 130.77, 128.79, 116.40, 114.58, 60.54, 59.45, 46.45, 14.48.


HRMS (ESI) m/z $[\text{M} + \text{H}]^+$ calculated for $\text{C}_{11}\text{H}_{14}\text{N}_2\text{O}_3\text{S}$: 255.0798, found 255.0797.



***O*-methyl (Z)-4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1*H*-pyrazol-1-yl)but-3-enethioate (10):**

^1H NMR (500 MHz, CDCl_3) δ 7.86 (s, 1H), 7.79 (s, 1H), 6.83 (d, $J = 9.3$ Hz, 1H), 5.89 – 5.51 (m, 1H), 4.11 (s, 3H), 4.09 (dd, $J = 6.9, 2.0$ Hz, 3H), 1.32 (s, 14H).

^{13}C NMR (126 MHz, CDCl_3) δ 146.62, 137.39, 126.09, 114.84, 83.65, 59.30, 44.02, 24.93.




O-methyl (E)-4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl)but-3-enethioate (10):

^1H NMR (500 MHz, CDCl_3) δ 7.87 (s, 1H), 7.84 (s, 1H), 6.92 (d, $J = 14.1$ Hz, 1H), 6.30 (dt, $J = 14.5, 7.6$ Hz, 1H), 4.09 (s, 3H), 3.66 – 3.50 (m, 2H), 1.32 (s, 12H).

^{13}C NMR (126 MHz, CDCl_3) δ 220.51, 146.68, 134.64, 129.07, 112.72, 83.66, 59.42, 46.77, 24.93.

HRMS (ESI) m/z $[\text{M} + \text{H}]^+$ calculated for $\text{C}_{14}\text{H}_{21}\text{BN}_2\text{O}_3\text{S}$: 309.1439, found 309.1439.




O-methyl (E)-4-(4-methoxy-1H-pyrazol-1-yl)but-3-enethioate (11):

^1H NMR (500 MHz, CDCl_3) δ 7.34 (s, 1H), 7.27 (s, 1H), 6.82 (dt, $J = 14.2, 1.4$ Hz, 2H), 6.00 (dt, $J = 14.3, 7.5$ Hz, 2H), 4.10 (s, 5H), 3.76 (s, 5H), 3.55 (dd, $J = 7.5, 1.4$ Hz, 3H).

^{13}C NMR (101 MHz, CDCl_3) δ 220.96, 148.12, 130.37, 129.33, 110.79, 109.41, 59.38, 58.88, 46.63.

HRMS (ESI) m/z $[\text{M} + \text{H}]^+$ calculated for $\text{C}_9\text{H}_{12}\text{N}_2\text{O}_2\text{S}$: 213.0692, found 213.0692.




O-methyl (E)-4-(4-(trifluoromethyl)-1H-pyrazol-1-yl)but-3-enethioate (12):

^1H NMR (500 MHz, CDCl_3) δ 7.86 (s, 1H), 7.78 (s, 1H), 6.90 (dt, 1H), 6.39 (dt, $J = 14.1, 7.6$ Hz, 1H), 4.11 (s, 3H), 3.59 (dd, $J = 7.6, 1.4$ Hz, 2H).

^{13}C NMR (126 MHz, CDCl_3) δ 219.62, 137.97 (q, $J = 2.7$ Hz), 128.54, 126.80 (d, $J = 3.9$ Hz), 125.05 – 118.32 (m), 115.03, 114.76, 59.34, 46.18.


HRMS (ESI) m/z $[\text{M} + \text{H}]^+$ calculated for $\text{C}_9\text{H}_9\text{F}_3\text{N}_2\text{OS}$: 251.0460, found 251.0460.



O-methyl (*E*)-4-(4-phenyl-1*H*-pyrazol-1-yl)but-3-enthioate (13):

^1H NMR (400 MHz, CDCl_3) δ 7.90 (s, 1H), 7.82 (s, 1H), 7.48 (d, $J = 6.5$ Hz, 2H), 7.38 (d, $J = 6.9$ Hz, 2H), 7.25 (s, 1H), 6.86 (t, $J = 7.2$ Hz, 1H), 5.64 (t, $J = 7.3$ Hz, 1H), 4.44 – 3.98 (m, 5H).

^{13}C NMR (101 MHz, CDCl_3) δ 221.38, 138.66, 131.90, 129.05, 127.04, 126.96, 126.49, 125.82, 123.69, 113.99, 59.38, 44.04.




O-methyl (*Z*)-4-(4-phenyl-1*H*-pyrazol-1-yl)but-3-enthioate (13):

^1H NMR (400 MHz, CDCl_3) δ 7.87 (s, 1H), 7.82 (s, 1H), 7.49 (s, 2H), 7.37 (d, $J = 7.5$ Hz, 2H), 7.27 – 7.18 (m, 1H), 6.94 (dt, $J = 14.4, 4.0$ Hz, 1H), 6.26 (dt, $J = 13.6, 6.7$ Hz, 1H), 4.10 (dd, $J = 5.2, 2.6$ Hz, 3H), 3.60 (d, $J = 6.7$ Hz, 2H).

^{13}C NMR (101 MHz, CDCl_3) δ 220.66, 138.67, 131.90, 129.48, 129.05, 127.00, 125.79, 124.41, 123.99, 111.60, 59.46, 46.71.


HRMS (ESI) m/z $[\text{M} + \text{H}]^+$ calculated for $\text{C}_{14}\text{H}_{14}\text{N}_2\text{OS}$: 259.0900, found 259.0898.



O-methyl (*Z*)-4-(4-acetyl-1*H*-pyrazol-1-yl)but-3-enthioate (14):

^1H NMR (500 MHz, CDCl_3) δ 8.02 (s, 1H), 7.98 (s, 1H), 6.81 (dt, $J = 9.3, 1.9$ Hz, 1H), 5.78 (dt, $J = 9.4, 7.2$ Hz, 1H), 4.10 (s, 3H), 4.01 (dd, $J = 7.3, 1.8$ Hz, 2H), 2.43 (s, 3H).

^{13}C NMR (126 MHz, CDCl_3) δ 220.38, 191.84, 141.25, 132.55, 125.82, 124.37, 117.20, 59.29, 43.73, 28.06.




O-methyl (E)-4-(4-acetyl-1H-pyrazol-1-yl)but-3-enethioate (14)

^1H NMR (500 MHz, CDCl_3) δ 8.03 (s, 1H), 7.97 (s, 1H), 6.90 (dt, $J = 14.0, 1.4$ Hz, 1H), 6.42 (dt, $J = 14.0, 7.6$ Hz, 1H), 4.10 (s, 3H), 3.59 (dd, $J = 7.6, 1.4$ Hz, 2H), 2.44 (s, 3H).

^{13}C NMR (126 MHz, CDCl_3) δ 219.65, 191.78, 141.35, 129.75, 128.56, 124.92, 115.05, 59.35, 46.28, 28.01.

HRMS (ESI) m/z $[\text{M} + \text{H}]^+$ calculated for $\text{C}_{10}\text{H}_{12}\text{N}_2\text{O}_2\text{S}$: 225.0692, found 225.0691.




O-methyl (E)-4-(3-(tert-butyl)-1H-pyrazol-1-yl)but-3-enethioate (15):

^1H NMR (500 MHz, CDCl_3) δ 7.44 (dd, $J = 28.4, 2.5$ Hz, 1H), 6.99 – 6.63 (m, 1H), 6.18 (dd, $J = 11.8, 2.5$ Hz, 1H), 6.15 – 5.41 (m, 1H), 4.10 (d, $J = 8.6$ Hz, 3H), 4.39 – 3.36 (m, 2H), 1.31 (s, 9H).

^{13}C NMR (126 MHz, CDCl_3) δ 221.70 (d, $J = 134.7$ Hz), 163.68, 130.34 (d, $J = 92.2$ Hz), 127.15 (d, $J = 152.3$ Hz), 110.88 (d, $J = 240.8$ Hz), 103.39 (d, $J = 113.0$ Hz), 59.29 (d, $J = 21.9$ Hz), 45.66 (d, $J = 336.4$ Hz), 32.69 – 29.52 (m), 30.51 (d, $J = 6.8$ Hz).


HRMS (ESI) m/z $[\text{M} + \text{H}]^+$ calculated for $\text{C}_{12}\text{H}_{18}\text{N}_2\text{OS}$: 239.1213, found 239.1211.



O-methyl (Z)-4-(3-methyl-1H-pyrazol-1-yl)but-3-enethioate (16):

^1H NMR (400 MHz, CDCl_3) δ 7.45 (d, $J = 2.4$ Hz, 1H), 6.76 (dt, $J = 9.4, 1.8$ Hz, 1H), 6.10 (d, $J = 2.3$ Hz, 1H), 5.50 (dt, $J = 9.4, 7.1$ Hz, 1H), 4.11 (s, 3H), 4.07 (dd, $J = 7.2, 1.8$ Hz, 2H), 2.30 (s, 4H).

^{13}C NMR (101 MHz, CDCl_3) δ 221.61, 150.25, 131.05, 126.46, 112.32, 106.23, 59.12, 44.08, 13.68.




***O*-methyl (*E*)-4-(3-methyl-1*H*-pyrazol-1-yl)but-3-enthioate (16):**

¹H NMR (400 MHz, CDCl₃) δ 7.44 (d, *J* = 2.4 Hz, 1H), 6.84 (dt, *J* = 14.1, 1.4 Hz, 1H), 6.16 (dt, *J* = 14.1, 7.6 Hz, 1H), 6.11 (d, *J* = 2.3 Hz, 1H), 4.09 (s, 3H), 3.56 (dd, *J* = 7.6, 1.4 Hz, 2H), 2.30 (s, 3H).

¹³C NMR (101 MHz, CDCl₃) δ 220.85, 150.45, 129.25, 128.50, 110.07, 106.89, 59.24, 46.83, 13.63.


HRMS (ESI) *m/z* [M + H]⁺ calculated for C₉H₁₂N₂OS: 197.0743, found 197.0743.



***O*-methyl (*Z*)-4-(1*H*-benzo[d][1,2,3]triazol-1-yl)but-3-enthioate (17):**

¹H NMR (500 MHz, CDCl₃) δ 8.09 (d, *J* = 8.3 Hz, 1H), 7.64 – 7.49 (m, 2H), 7.42 (ddd, *J* = 8.2, 4.9, 3.1 Hz, 1H), 7.16 (dt, *J* = 9.1, 2.0 Hz, 1H), 6.21 (dt, *J* = 9.1, 7.0 Hz, 1H), 4.11 (s, 3H), 4.08 (dd, *J* = 6.9, 1.9 Hz, 2H).

¹³C NMR (126 MHz, CDCl₃) δ 220.48, 145.30, 132.85, 128.27, 124.66, 120.99, 120.59, 120.30, 109.58, 59.34, 44.28.




***O*-methyl (*E*)-4-(1*H*-benzo[d][1,2,3]triazol-1-yl)but-3-enthioate (17):**

¹H NMR (500 MHz, CDCl₃) δ 8.09 (d, *J* = 8.3 Hz, 1H), 7.74 (d, *J* = 8.3 Hz, 1H), 7.56 (ddd, *J* = 8.3, 6.8, 0.9 Hz, 1H), 7.50 – 7.36 (m, 2H), 6.71 (dt, *J* = 14.7, 7.5 Hz, 1H), 4.15 (s, 2H), 3.73 (dd, *J* = 7.6, 1.4 Hz, 2H).

¹³C NMR (126 MHz, CDCl₃) δ 219.87, 146.41, 131.61, 128.45, 125.53, 124.70, 120.50, 116.55, 110.39, 59.54, 46.92.

HRMS (ESI) *m/z* [M + H]⁺ calculated for C₁₁H₁₁N₃OS: 234.0496, found 234.0493.




***O*-methyl (*E*)-4-(1*H*-benzo[*d*]imidazol-1-yl)but-3-enethioate (18):**

^1H NMR (500 MHz, CDCl_3) δ 8.69 (s, 1H), 7.95 – 7.82 (m, 1H), 7.74 – 7.56 (m, 1H), 7.49 – 7.34 (m, 2H), 7.05 (dt, $J = 14.3, 1.4$ Hz, 1H), 6.44 (dt, $J = 14.6, 7.5$ Hz, 1H), 4.15 (s, 3H), 3.69 (dd, $J = 7.5, 1.3$ Hz, 2H).

^{13}C NMR (126 MHz, CDCl_3) δ 218.46, 140.13, 133.67, 124.99, 124.45, 123.68, 119.35, 118.62, 117.50, 111.09, 59.43, 46.42.


HRMS (ESI) m/z $[\text{M} + \text{H}]^+$ calculated for $\text{C}_{12}\text{H}_{12}\text{N}_2\text{OS}$: 233.0743, found 233.0743



***O*-methyl (*Z*)-4-(3,5-dimethyl-1*H*-pyrazol-1-yl)but-3-enethioate (19):**

^1H NMR (500 MHz, CDCl_3) δ 6.61 (d, $J = 9.3$ Hz, 1H), 5.83 (s, 1H), 5.58 (dt, $J = 9.3, 6.8$ Hz, 1H), 4.16 (dd, $J = 6.8, 1.8$ Hz, 3H), 4.10 (s, 4H), 2.23 (d, $J = 4.1$ Hz, 8H).

^{13}C NMR (126 MHz, CDCl_3) δ 222.77, 149.35, 140.01, 123.11, 114.09, 105.90, 59.16, 44.11, 13.86, 11.31.




***O*-methyl (*E*)-4-(3,5-dimethyl-1*H*-pyrazol-1-yl)but-3-enethioate (19):**

^1H NMR (500 MHz, CDCl_3) δ 6.74 (dd, $J = 13.7, 1.6$ Hz, 1H), 6.29 (dt, $J = 14.4, 7.6$ Hz, 1H), 5.84 (s, 1H), 4.08 (s, 3H), 3.58 (d, $J = 7.7$ Hz, 2H), 2.26 (s, 3H), 2.24 (s, 3H).

^{13}C NMR (126 MHz, CDCl_3) δ 221.25, 149.98, 139.11, 125.97, 110.92, 106.77, 59.41, 47.59, 13.77, 11.11.


HRMS (ESI) m/z $[\text{M} + \text{H}]^+$ calculated for $\text{C}_{10}\text{H}_{14}\text{N}_2\text{OS}$: 211.0900, found 211.0897.



***O*-methyl (*Z*)-4-(3,5-dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1*H*-pyrazol-1-yl)but-3-enethioate (20):**

¹H NMR (500 MHz, CDCl₃) δ 6.63 (d, *J* = 9.3 Hz, 1H), 5.64 (dt, *J* = 9.3, 6.8 Hz, 1H), 4.11 (dd, *J* = 7.1, 2.1 Hz, 2H), 4.09 (s, 3H), 2.40 (s, 3H), 2.34 (s, 3H), 1.29 (s, 12H).

¹³C NMR (126 MHz, CDCl₃) δ 222.47, 155.95, 148.25, 123.20, 115.73, 82.77, 59.13, 44.12, 25.02, 14.33, 11.50.




***O*-methyl (*E*)-4-(3,5-dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1*H*-pyrazol-1-yl)but-3-enethioate (20):**

¹H NMR (500 MHz, CDCl₃) δ 6.83 – 6.66 (m, 1H), 6.34 (dt, *J* = 13.7, 7.7 Hz, 1H), 4.07 (s, 3H), 3.58 (dd, *J* = 7.6, 1.4 Hz, 2H), 2.43 (s, 3H), 2.35 (s, 3H), 1.28 (s, 12H).

¹³C NMR (126 MHz, CDCl₃) δ 220.98, 156.56, 147.08, 125.53, 111.97, 82.65, 59.29, 47.54, 24.89, 14.14, 11.10.

HRMS (ESI) *m/z* [*M* + *H*]⁺ calculated for C₁₆H₂₅BN₂O₃S: 337.1752, found 337.1750.




***O*-methyl (*E*)-4-(4-bromo-3,5-dimethyl-1*H*-pyrazol-1-yl)but-3-enethioate (21):**

¹H NMR (500 MHz, CDCl₃) δ 6.74 (dt, *J* = 13.7, 1.3 Hz, 1H), 6.33 (dt, *J* = 13.7, 7.7 Hz, 1H), 4.09 (s, 3H), 3.58 (dd, *J* = 7.6, 1.4 Hz, 2H), 2.28 (s, 3H), 2.24 (s, 3H).

¹³C NMR (126 MHz, CDCl₃) δ 220.77, 148.39, 137.05, 126.20, 112.32, 96.24, 59.45, 47.24, 12.58, 10.46.


HRMS (ESI) *m/z* [*M* + *H*]⁺ calculated for C₁₀H₁₃BrN₂OS: 289.0005, found 289.0003.



Ethyl (*Z*)-1-(4-methoxy-4-thioxobut-1-en-1-yl)-3,5-dimethyl-1*H*-pyrazole-4-carboxylate (22):

¹H NMR (400 MHz, CDCl₃) δ 6.66 (dt, *J* = 9.1, 1.8 Hz, 1H), 5.84 (dt, *J* = 9.1, 6.9 Hz, 1H), 4.29 (q, *J* = 7.1 Hz, 2H), 4.10 (s, 3H), 4.01 (dd, *J* = 6.9, 1.8 Hz, 2H), 2.51 (s, 3H), 2.43 (s, 3H), 1.36 (t, *J* = 7.1 Hz, 3H).

^{13}C NMR (101 MHz, CDCl_3) δ 221.47, 164.56, 151.62, 144.75, 123.02, 119.13, 110.25, 59.91, 59.20, 44.01, 14.63, 14.53, 11.38.




Ethyl (*E*)-1-(4-methoxy-4-thioxobut-1-en-1-yl)-3,5-dimethyl-1*H*-pyrazole-4-carboxylate (22):

^1H NMR (400 MHz, CDCl_3) δ 6.79 (dt, $J = 13.7, 1.4$ Hz, 1H), 6.47 (dt, $J = 13.7, 7.7$ Hz, 1H), 4.29 (q, $J = 7.1$ Hz, 2H), 4.10 (s, 3H), 3.61 (dd, $J = 7.6, 1.4$ Hz, 2H), 2.56 (s, 3H), 2.44 (s, 3H), 1.36 (t, $J = 7.1$ Hz, 3H).

^{13}C NMR (101 MHz, CDCl_3) δ 220.28, 164.29, 152.11, 143.42, 125.02, 114.77, 110.85, 59.77, 59.31, 47.16, 14.47, 14.35, 10.85.

HRMS (ESI) m/z $[\text{M} + \text{H}]^+$ calculated for $\text{C}_{13}\text{H}_{18}\text{BrN}_2\text{O}_3\text{S}$: 283.1111, found 283.1109.




***O*-methyl (*E*)-2-methyl-4-(1*H*-pyrazol-1-yl)but-3-enethioate (23):**

^1H NMR (400 MHz, CDCl_3) δ 7.59 (d, $J = 1.8$ Hz, 1H), 7.56 (dd, $J = 2.5, 0.7$ Hz, 1H), 6.93 (dd, $J = 14.2, 1.0$ Hz, 1H), 6.33 (dd, $J = 2.5, 1.8$ Hz, 1H), 6.20 (dd, $J = 14.2, 8.6$ Hz, 1H), 4.09 (s, 3H), 3.76 – 3.53 (m, 1H), 1.45 (d, $J = 7.0$ Hz, 3H).

^{13}C NMR (101 MHz, CDCl_3) δ 225.56, 140.92, 127.90, 127.70, 118.23, 107.10, 59.33, 50.88, 20.74.


HRMS (ESI) m/z $[\text{M} + \text{H}]^+$ calculated for $\text{C}_9\text{H}_{12}\text{N}_2\text{OS}$: 197.0743, found 197.0741.



***O*-ethyl (*Z*)-4-(1*H*-pyrazol-1-yl)but-3-enethioate (24):**

^1H NMR (400 MHz, CDCl_3) δ 7.63 (d, $J = 1.8$ Hz, 1H), 7.58 (dd, $J = 2.4, 0.7$ Hz, 1H), 6.85 (dt, $J = 9.4, 1.9$ Hz, 1H), 6.33 (dd, $J = 2.5, 1.8$ Hz, 1H), 5.63 (dt, $J = 9.4, 7.1$ Hz, 1H), 4.54 (t, $J = 7.1$ Hz, 2H), 4.04 (dd, $J = 7.1, 1.8$ Hz, 2H), 1.41 (t, $J = 7.1$ Hz, 3H).

^{13}C NMR (101 MHz, CDCl_3) δ 220.58, 140.73, 130.31, 126.42, 113.81, 106.28, 68.53, 44.32, 13.57.




O-ethyl (*E*)-4-(1*H*-pyrazol-1-yl)but-3-enethioate (24):

^1H NMR (500 MHz, CDCl_3) δ 7.58 (d, $J = 1.8$ Hz, 1H), 7.56 (d, $J = 2.5$ Hz, 1H), 6.92 (dt, $J = 14.1$, 1.5 Hz, 1H), 6.32 (t, $J = 2.1$ Hz, 1H), 6.23 (dt, $J = 14.1$, 7.6 Hz, 1H), 4.51 (q, $J = 7.1$ Hz, 2H), 3.54 (dd, $J = 7.6$, 1.4 Hz, 2H), 1.39 (t, $J = 7.1$ Hz, 3H).

^{13}C NMR (126 MHz, CDCl_3) δ 219.97, 140.81, 129.34, 127.54, 111.53, 106.98, 68.74, 47.07, 13.60.

HRMS (ESI) m/z $[\text{M} + \text{H}]^+$ calculated for $\text{C}_9\text{H}_{12}\text{N}_2\text{OS}$: 197.0743, found 197.0743.




O-isopropyl (*E*)-4-(1*H*-pyrazol-1-yl)but-3-enethioate (25):

^1H NMR (500 MHz, CDCl_3) δ 7.59 (d, $J = 1.7$ Hz, 1H), 7.58 (d, $J = 2.5$ Hz, 1H), 6.94 (dt, $J = 14.1$, 1.5 Hz, 1H), 6.34 (t, $J = 2.1$ Hz, 1H), 6.23 (dt, $J = 14.0$, 7.5 Hz, 1H), 5.63 (p, $J = 6.2$ Hz, 1H), 3.51 (dd, $J = 7.5$, 1.4 Hz, 2H), 1.36 (d, $J = 6.3$ Hz, 7H).

^{13}C NMR (126 MHz, CDCl_3) δ 219.31, 140.89, 129.39, 127.62, 111.75, 107.09, 76.04, 47.68, 21.15.


HRMS (ESI) m/z $[\text{M} + \text{H}]^+$ calculated for $\text{C}_{10}\text{H}_{14}\text{N}_2\text{OS}$: 211.0900, found 211.0899.



O-isopropyl (*Z*)-4-(1*H*-pyrazol-1-yl)but-3-enethioate (25):

^1H NMR (500 MHz, CDCl_3) δ 7.62 (d, $J = 1.8$ Hz, 2H), 7.59 (d, $J = 2.5$ Hz, 2H), 6.85 (dt, $J = 9.4$, 1.9 Hz, 2H), 6.33 (t, $J = 2.1$ Hz, 2H), 5.67 (p, $J = 6.2$ Hz, 2H), 5.62 (dt, $J = 9.4$, 7.1 Hz, 2H), 3.97 (dd, $J = 7.1$, 1.9 Hz, 4H), 1.36 (d, $J = 6.2$ Hz, 12H).

^{13}C NMR (126 MHz, CDCl_3) δ 219.87, 140.85, 130.44, 126.56, 113.98, 106.43, 75.84, 45.00, 21.16.




O-benzyl (E)-4-(1H-pyrazol-1-yl)but-3-enethioate (26):

^1H NMR (400 MHz, CDCl_3) δ 7.60 (d, $J = 1.8$ Hz, 1H), 7.57 (dd, $J = 2.4, 0.7$ Hz, 1H), 7.47 – 7.33 (m, 5H), 6.95 (dt, $J = 14.2, 1.4$ Hz, 1H), 6.34 (dd, $J = 2.5, 1.8$ Hz, 1H), 6.27 (dt, $J = 14.1, 7.6$ Hz, 1H), 5.51 (s, 2H), 3.61 (dd, $J = 7.6, 1.4$ Hz, 2H).

^{13}C NMR (101 MHz, CDCl_3) δ 219.56, 140.82, 134.82, 129.50, 128.66, 128.62, 128.50, 127.49, 111.42, 106.98, 74.20, 46.88.


HRMS (ESI) m/z $[\text{M} + \text{H}]^+$ calculated for $\text{C}_{14}\text{H}_{14}\text{N}_2\text{OS}$: 259.0900, found 259.0898.



O-benzyl (Z)-4-(1H-pyrazol-1-yl)but-3-enethioate (26):

^1H NMR (400 MHz, CDCl_3) δ 7.61 (d, $J = 1.8$ Hz, 1H), 7.55 (d, $J = 2.4$ Hz, 1H), 7.43 – 7.33 (m, 5H), 6.85 (dt, $J = 9.4, 1.8$ Hz, 1H), 6.32 (t, $J = 2.2$ Hz, 1H), 5.64 (dt, $J = 9.4, 7.1$ Hz, 1H), 5.52 (s, 2H), 4.11 (dd, $J = 7.1, 1.9$ Hz, 2H).

^{13}C NMR (101 MHz, CDCl_3) δ 220.25, 140.77, 134.93, 130.33, 128.62, 128.54, 128.42, 126.47, 113.54, 106.29, 74.05, 44.26.




Methyl (E)-4-(1H-pyrazol-1-yl)but-3-enoate (27): The title compound was prepared according to the general procedure D. The crude residue was purified by column chromatography on silica gel with an eluent of hexanes/ethyl acetate (2:1) to furnish the pure compound as a yellow oil in 76% yield.

^1H NMR (500 MHz, CDCl_3) δ 7.59 (d, $J = 1.8$ Hz, 1H), 7.58 (d, $J = 2.4$ Hz, 1H), 6.97 (d, $J = 14.2$ Hz, 1H), 6.34 (t, $J = 2.1$ Hz, 1H), 6.15 (dt, $J = 14.2, 7.5$ Hz, 1H), 3.72 (s, 3H), 3.21 (dd, $J = 7.5, 1.5$ Hz, 2H).

^{13}C NMR (126 MHz, CDCl_3) δ 171.68, 140.97, 130.08, 127.60, 109.11, 107.18, 52.23, 35.00.

HRMS (ESI) m/z $[\text{M} + \text{H}]^+$ calculated for $\text{C}_8\text{H}_{10}\text{N}_2\text{O}_2$: 167.0815, found 167.0814.




Methyl (E)-4-(4-methyl-1H-pyrazol-1-yl)but-3-enoate (28):

¹H NMR (500 MHz, CDCl₃) δ 7.36 (d, *J* = 13.5 Hz, 3H), 6.93 – 6.76 (m, 1H), 6.00 (dt, *J* = 14.6, 7.5 Hz, 1H), 3.70 (s, 4H), 3.17 (dd, *J* = 7.5, 1.5 Hz, 3H), 2.07 (s, 4H).

¹³C NMR (126 MHz, CDCl₃) δ 171.74, 141.63, 130.22, 125.96, 117.82, 107.69, 52.12, 34.98, 8.92.

HRMS (ESI) *m/z* [M + H]⁺ calculated for C₉H₁₂N₂O₂: 181.0972, found 181.0971.




methyl (E)-4-(4-bromo-3,5-dimethyl-1H-pyrazol-1-yl)but-3-enoate (29):

¹H NMR (500 MHz, CDCl₃) δ 6.77 (d, *J* = 13.8 Hz, 1H), 6.25 (dt, *J* = 13.7, 7.6 Hz, 2H), 3.71 (s, 5H), 3.19 (dd, *J* = 7.6, 1.4 Hz, 3H), 2.27 (s, 5H), 2.24 (s, 5H).

¹³C NMR (126 MHz, CDCl₃) δ 171.62, 148.40, 136.98, 126.67, 110.15, 96.25, 52.19, 35.27, 12.55, 10.41.

HRMS (ESI) *m/z* [M + H]⁺ calculated for C₁₀H₁₃BrN₂O₂: 273.0233, found 273.0231.




4-bromo-1-(5-methoxy-2,3-dihydrofuran-2-yl)-1H-pyrazole (30):

¹H NMR (500 MHz, CDCl₃) δ 7.61 (s, 1H), 7.53 (s, 1H), 6.89 (dt, *J* = 14.3, 1.5 Hz, 1H), 6.11 (dt, *J* = 14.2, 7.5 Hz, 1H), 3.72 (s, 3H), 3.20 (dd, *J* = 7.5, 1.5 Hz, 2H).

¹³C NMR (126 MHz, CDCl₃) δ 171.23, 141.24, 129.57, 127.35, 110.00, 95.19, 52.15, 34.62.


HRMS (ESI) *m/z* [M + H]⁺ calculated for C₈H₉BrN₂O₂: 244.9920, found 244.9920.



O-methyl (Z)-4-(4-(7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)but-3-enthioate (31):

^1H NMR (400 MHz, CDCl_3) δ 8.85 (s, 1H), 8.38 (s, 1H), 8.37 (s, 1H), 7.40 (d, $J = 3.7$ Hz, 1H), 6.93 (dt, $J = 9.4, 1.8$ Hz, 1H), 6.80 (d, $J = 3.8$ Hz, 1H), 5.77 (dt, $J = 9.3, 7.3$ Hz, 1H), 5.67 (s, 2H), 4.14 (s, 3H), 4.16 – 4.10 (m, 2H), 3.61 – 3.48 (m, 2H), 1.05 – 0.69 (m, 2H), -0.06 (s, 9H).

^{13}C NMR (101 MHz, CDCl_3) δ 220.82, 152.23, 151.90, 150.53, 140.59, 130.73, 128.47, 126.24, 122.15, 115.71, 114.34, 100.74, 72.80, 66.59, 59.24, 43.95, 17.74, -1.46.




***O*-methyl (*E*)-4-(4-(7-((2-(trimethylsilyl)ethoxy)methyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-yl)-1*H*-pyrazol-1-yl)but-3-enethioate (31):**

^1H NMR (400 MHz, CDCl_3) δ 8.85 (s, 1H), 8.39 (s, 1H), 8.33 (s, 1H), 7.40 (d, $J = 3.7$ Hz, 1H), 7.01 (dt, $J = 14.2, 1.5$ Hz, 1H), 6.79 (d, $J = 3.7$ Hz, 1H), 6.43 (dt, $J = 14.1, 7.6$ Hz, 1H), 5.67 (s, 2H), 4.12 (s, 3H), 3.63 (dd, $J = 7.6, 1.4$ Hz, 2H), 3.60 – 3.42 (m, 2H), 1.06 – 0.77 (m, 2H), -0.06 (s, 9H).

^{13}C NMR (101 MHz, CDCl_3) δ 220.02, 152.25, 151.88, 150.47, 140.58, 129.04, 128.49, 127.84, 122.81, 114.31, 113.47, 100.74, 72.80, 66.59, 59.31, 46.51, 17.74, -1.46.


HRMS (ESI) m/z $[\text{M} + \text{H}]^+$ calculated for $\text{C}_{20}\text{H}_{27}\text{N}_5\text{O}_2\text{SSi}$: 430.1728, found 430.1727.



***O*-methyl (*Z*)-4-(4-(1-((2-(trimethylsilyl)ethoxy)methyl)-1*H*-pyrrolo[3,2-*c*]pyridin-4-yl)-1*H*-pyrazol-1-yl)but-3-enethioate (32):**

^1H NMR (500 MHz, CDCl_3) δ 8.33 (d, $J = 5.0$ Hz, 1H), 8.12 (s, 1H), 8.10 (s, 1H), 7.41 (d, $J = 3.6$ Hz, 1H), 7.19 (d, $J = 5.0$ Hz, 1H), 6.93 (dt, $J = 9.4, 1.8$ Hz, 1H), 6.72 (d, $J = 3.7$ Hz, 1H), 5.72 (d, $J = 13.0$ Hz, 3H), 4.14 (s, 2H), 4.13 (dd, $J = 7.3, 1.8$ Hz, 2H), 3.77 – 3.36 (m, 2H), 1.04 – 0.69 (m, 2H), -0.06 (s, 9H).

^{13}C NMR (126 MHz, CDCl_3) δ 222.40, 150.33, 144.96, 141.24, 133.80, 130.33, 129.51, 127.83, 122.34, 118.91, 116.34, 115.22, 101.74, 74.46, 67.68, 60.72, 45.43, 19.22, -0.00.




***O*-methyl (*E*)-4-(4-(1-((2-(trimethylsilyl)ethoxy)methyl)-1*H*-pyrrolo[3,2-*c*]pyridin-4-yl)-1*H*-pyrazol-1-yl)but-3-enethioate (32):**

^1H NMR (500 MHz, CDCl_3) δ 8.32 (d, $J = 5.0$ Hz, 1H), 8.09 (s, 1H), 8.06 (s, 1H), 7.41 (d, $J = 3.6$ Hz, 1H), 7.18 (s, 1H), 7.01 (d, $J = 14.1$ Hz, 1H), 6.71 (d, $J = 3.6$ Hz, 1H), 6.37 (dt, $J = 14.6, 7.5$ Hz, 1H), 5.70 (s, 2H), 4.12 (s, 3H), 3.63 (d, $J = 7.5$ Hz, 2H), 3.56 (t, $J = 8.2$ Hz, 2H), 0.92 (t, $J = 8.2$ Hz, 2H), -0.07 (s, 9H).

^{13}C NMR (126 MHz, CDCl_3) δ 221.71, 150.33, 144.96, 141.30, 133.79, 130.63, 129.51, 127.37, 123.04, 118.90, 115.23, 113.99, 101.73, 74.46, 67.67, 60.79, 48.00, 19.22, 0.00.

HRMS (ESI) m/z $[\text{M} + \text{H}]^+$ calculated for $\text{C}_{21}\text{H}_{28}\text{N}_4\text{O}_2\text{SSi}$: 429.1775, found 429.1775.




((3*aR*,4*R*,6*R*,6*aR*)-6-methoxy-2,2-dimethyltetrahydrofuro[3,4-*d*][1,3]dioxol-4-yl)methyl 1-((*E*)-4-methoxy-4-thioxobut-1-en-1-yl)-1*H*-pyrazole-4-carboxylate (33):

^1H NMR (400 MHz, CDCl_3) δ 8.08 (d, $J = 0.6$ Hz, 1H), 8.00 (s, 1H), 6.90 (dt, $J = 14.1, 1.5$ Hz, 1H), 6.41 (dt, $J = 14.0, 7.6$ Hz, 1H), 5.00 (s, 1H), 4.72 (dd, $J = 6.0, 1.0$ Hz, 1H), 4.63 (d, $J = 5.9$ Hz, 1H), 4.47 (td, $J = 6.8, 1.1$ Hz, 1H), 4.28 (dd, $J = 6.8, 0.7$ Hz, 2H), 4.10 (s, 3H), 3.59 (dd, $J = 7.6, 1.4$ Hz, 2H), 3.32 (s, 3H), 1.49 (d, $J = 0.7$ Hz, 4H), 1.33 (d, $J = 0.7$ Hz, 4H).

^{13}C NMR (101 MHz, CDCl_3) δ 219.63, 162.03, 142.14, 130.86, 128.60, 115.52, 114.81, 112.63, 109.51, 85.30, 84.36, 81.91, 64.62, 59.31, 54.94, 46.30, 26.47, 25.03.


HRMS (ESI) m/z $[M + H]^+$ calculated for $C_{18}H_{24}N_2O_7S$: 413.1377, found 413.1377.



((3aR,4R,6R,6aR)-6-methoxy-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methyl 1-((Z)-4-methoxy-4-thioxobut-1-en-1-yl)-1H-pyrazole-4-carboxylate (33):

1H NMR (400 MHz, $CDCl_3$) δ 8.06 (s, 1H), 8.03 (s, 1H), 6.81 (dt, $J = 9.2, 1.9$ Hz, 1H), 5.79 (dt, $J = 9.4, 7.2$ Hz, 1H), 5.01 (s, 1H), 4.77 – 4.68 (m, 1H), 4.63 (d, $J = 5.9$ Hz, 1H), 4.47 (d, $J = 1.1$ Hz, 1H), 4.29 (dd, $J = 6.7, 1.9$ Hz, 2H), 4.12 (s, 3H), 4.04 (dd, $J = 7.2, 1.8$ Hz, 2H), 3.33 (s, 3H), 1.50 (d, $J = 0.7$ Hz, 3H), 1.39 – 1.19 (m, 3H).

^{13}C NMR (101 MHz, $CDCl_3$) δ 220.40, 162.08, 142.05, 133.58, 125.73, 117.06, 114.99, 112.62, 109.52, 85.32, 84.37, 81.91, 64.60, 59.21, 54.93, 43.69, 26.47, 25.02.




O-methyl (E)-4-(6-chloro-7H-purin-7-yl)but-3-enethioate (34):

1H NMR (400 MHz, $CDCl_3$) δ 8.80 (s, 1H), 8.32 (s, 1H), 7.12 (dt, $J = 14.4, 1.4$ Hz, 1H), 6.74 (dt, $J = 14.4, 7.5$ Hz, 1H), 4.14 (s, 3H), 3.68 (dd, $J = 7.5, 1.4$ Hz, 2H).

^{13}C NMR (101 MHz, $CDCl_3$) δ 219.17, 152.56, 151.53, 150.75, 142.55, 132.03, 122.02, 118.09, 59.38, 46.57.

HRMS (ESI) m/z $[M + H]^+$ calculated for $C_{10}H_9ClN_4OS$: 269.0258, found 269.0258.




1-(2-methoxy-2,3-dihydrobenzo[b]thiophen-3-yl)-1H-pyrazole (35):

^1H NMR (500 MHz, CDCl_3) δ 7.62 (d, $J = 1.8$ Hz, 1H), 7.56 (d, $J = 2.5$ Hz, 1H), 7.35 – 7.27 (m, 2H), 7.12 (td, $J = 7.4, 1.5$ Hz, 1H), 6.93 (d, $J = 7.6$ Hz, 1H), 6.35 (d, $J = 2.3$ Hz, 1H), 6.25 (d, $J = 5.0$ Hz, 1H), 5.33 (d, $J = 4.8$ Hz, 1H), 3.27 (s, 3H).

^{13}C NMR (126 MHz, CDCl_3) δ 139.51, 137.24, 136.47, 130.92, 129.46, 125.36, 124.99, 123.90, 106.24, 91.96, 72.19, 57.15.

HRMS (ESI) m/z $[\text{M} + \text{H}]^+$ calculated for $\text{C}_{12}\text{H}_{12}\text{N}_2\text{OS}$: 233.0743, found 233.0743.




1-(phenylsulfonyl)-2-(1H-pyrazol-1-yl)indoline (36):

^1H NMR (500 MHz, CDCl_3) δ 7.56 (d, $J = 2.5$ Hz, 1H), 7.51 – 7.44 (m, 2H), 7.43 – 7.33 (m, 3H), 7.32 – 7.22 (m, 2H), 7.15 – 7.11 (m, 1H), 7.08 (dd, $J = 7.5, 1.3$ Hz, 1H), 6.97 (td, $J = 7.5, 1.0$ Hz, 1H), 6.46 (dd, $J = 8.8, 2.2$ Hz, 1H), 6.11 (t, $J = 2.1$ Hz, 1H), 3.42 (dd, $J = 16.9, 2.2$ Hz, 1H), 3.33 (dd, $J = 16.9, 8.8$ Hz, 1H).

^{13}C NMR (126 MHz, CDCl_3) δ 140.70, 140.48, 138.69, 133.40, 129.39, 129.24, 129.19, 128.21, 126.85, 125.10, 124.72, 114.95, 106.28, 75.61, 36.00.

HRMS (ESI) m/z $[\text{M} + \text{H}]^+$ calculated for $\text{C}_{17}\text{H}_{15}\text{N}_3\text{O}_2\text{S}$: 181.0972, found 181.0971.




(2-(1H-pyrazol-1-yl)indolin-1-yl)(phenyl)methanone (37):

^1H NMR (500 MHz, CDCl_3) δ 7.53 – 7.07 (m, 8H), 7.07 – 6.82 (m, 2H), 6.67 – 6.41 (m, 1H), 6.05 (d, $J = 2.3$ Hz, 1H), 3.58 (dd, $J = 16.7, 8.4$ Hz, 1H), 3.26 (d, $J = 16.0$ Hz, 1H).

^{13}C NMR (126 MHz, CDCl_3) δ 169.62, 140.27, 135.57, 130.88, 129.52, 128.70, 128.38, 127.69, 127.10, 125.16, 124.75, 116.63, 105.91, 75.02, 36.49.

HRMS (ESI) m/z $[\text{M} + \text{H}]^+$ calculated for $\text{C}_{18}\text{H}_{15}\text{N}_3\text{O}$: 290.1288, found 290.1285.




tert-butyl 2-(1H-pyrazol-1-yl)indoline-1-carboxylate (38):

^1H NMR (500 MHz, $\text{DMSO}-d_6$) δ 7.76 (d, $J = 2.4$ Hz, 1H), 7.42 (d, $J = 1.7$ Hz, 1H), 7.26 (d, $J = 7.4$ Hz, 1H), 7.20 (td, $J = 7.7, 1.3$ Hz, 1H), 7.01 (td, $J = 7.5, 1.1$ Hz, 1H), 6.62 (dd, $J = 9.5, 2.1$ Hz, 1H), 6.23 (t, $J = 2.1$ Hz, 1H), 3.69 (dd, $J = 17.1, 9.4$ Hz, 1H), 3.21 (d, $J = 17.1$ Hz, 1H), 1.39 (s, 10H).

^{13}C NMR (126 MHz, DMSO- d_6) δ 151.12, 142.37, 139.76, 129.91, 129.07, 127.20, 124.50, 122.79, 114.05, 104.67, 81.04, 72.89, 33.58, 27.80.

HRMS (ESI) m/z $[\text{M} + \text{H}]^+$ calculated for $\text{C}_{16}\text{H}_{19}\text{N}_3\text{O}_2$: 286.1550, found 286.1550.




5-methyl-1-(phenylsulfonyl)-2-(1H-pyrazol-1-yl)indoline (39):

^1H NMR (500 MHz, CDCl_3) δ 7.67 (d, $J = 2.7$ Hz, 1H), 7.57 (d, $J = 7.8$ Hz, 2H), 7.54 – 7.43 (m, 2H), 7.37 (q, $J = 7.6$ Hz, 3H), 7.08 – 6.86 (m, 2H), 6.51 (d, $J = 8.9$ Hz, 1H), 6.21 (d, $J = 2.4$ Hz, 1H), 3.47 (d, $J = 16.8$ Hz, 1H), 3.34 (dd, $J = 16.8, 8.8$ Hz, 1H), 2.28 (s, 3H).

^{13}C NMR (126 MHz, CDCl_3) δ 140.64, 138.55, 138.06, 134.62, 133.35, 129.65, 129.16, 129.14, 128.76, 126.85, 125.73, 115.01, 106.24, 75.81, 35.87, 21.08.

HRMS (ESI) m/z $[\text{M} + \text{H}]^+$ calculated for $\text{C}_{18}\text{H}_{17}\text{N}_3\text{O}_2\text{S}$: 340.1114, found 340.1113.




5-iodo-1-(phenylsulfonyl)-2-(1H-pyrazol-1-yl)indoline (40):

^1H NMR (500 MHz, CDCl_3) δ 7.67 (s, 1H), 7.55 – 7.48 (m, 5H), 7.45 (s, 1H), 7.38 (t, $J = 7.8$ Hz, 2H), 7.21 (d, $J = 8.4$ Hz, 1H), 6.52 (d, $J = 8.9$ Hz, 1H), 6.22 (s, 1H), 3.52 (d, $J = 17.0$ Hz, 1H), 3.43 (dd, $J = 17.2, 8.9$ Hz, 1H).

^{13}C NMR (126 MHz, CDCl_3) δ 140.96, 140.36, 138.35, 137.02, 133.90, 133.56, 131.87, 129.54, 129.24, 126.71, 116.43, 106.32, 87.82, 75.29, 35.38.

HRMS (ESI) m/z $[\text{M} + \text{H}]^+$ calculated for $\text{C}_{17}\text{H}_{14}\text{IN}_3\text{O}_2\text{S}$: 451.9924, found 451.9922.




5-bromo-1-(phenylsulfonyl)-2-(1H-pyrazol-1-yl)indoline (41):

^1H NMR (500 MHz, CDCl_3) δ 7.60 (s, 1H), 7.46 (d, $J = 8.0$ Hz, 3H), 7.38 (s, 1H), 7.35 – 7.13 (m, 5H), 6.47 (d, $J = 8.9$ Hz, 1H), 6.15 (s, 1H), 3.47 (d, $J = 17.1$ Hz, 1H), 3.35 (dd, $J = 17.3, 8.9$ Hz, 1H).

^{13}C NMR (126 MHz, CDCl_3) δ 141.00, 139.72, 138.43, 133.62, 131.75, 131.14, 129.58, 129.31, 128.20, 126.79, 117.47, 116.13, 106.40, 75.57, 35.57.

HRMS (ESI) m/z $[\text{M} + \text{H}]^+$ calculated for $\text{C}_{17}\text{H}_{14}\text{BrN}_3\text{O}_2\text{S}$: 404.0063, found 404.0061.




5-fluoro-1-(phenylsulfonyl)-2-(1H-pyrazol-1-yl)indoline (42):

^1H NMR (500 MHz, CDCl_3) δ 7.70 (s, 1H), 7.55 (t, $J = 8.3$ Hz, 3H), 7.49 – 7.22 (m, 4H), 7.00 – 6.77 (m, 2H), 6.53 (d, $J = 8.9$ Hz, 1H), 6.24 (s, 1H), 3.54 (d, $J = 17.1$ Hz, 1H), 3.35 (dd, $J = 17.3$, 9.0 Hz, 1H).

^{13}C NMR (126 MHz, CDCl_3) δ 161.34, 159.41, 140.91, 138.29, 136.50, 133.61, 131.87 (d, $J = 8.8$ Hz), 129.45, 129.31, 126.86, 116.30 (d, $J = 8.6$ Hz), 114.84 (d, $J = 23.5$ Hz), 112.53 (d, $J = 24.7$ Hz), 76.01, 35.73.

HRMS (ESI) m/z $[\text{M} + \text{H}]^+$ calculated for $\text{C}_{17}\text{H}_{14}\text{FN}_3\text{O}_2\text{S}$: 344.0864, found 344.0861.




tert-butyl 7-methyl-2-(1H-pyrazol-1-yl)indoline-1-carboxylate (43):

^1H NMR (500 MHz, $\text{DMSO}-d_6$) δ 7.69 (d, $J = 2.4$ Hz, 1H), 7.41 (d, $J = 1.7$ Hz, 1H), 7.12 (dd, $J = 6.3$, 2.5 Hz, 1H), 7.07 – 6.92 (m, 2H), 6.67 (dd, $J = 8.3$, 1.3 Hz, 1H), 6.24 (t, $J = 2.1$ Hz, 1H), 3.78 (dd, $J = 16.7$, 8.3 Hz, 1H), 3.32 (d, $J = 16.8$ Hz, 1H), 2.18 (s, 3H), 1.51 (s, 9H).

^{13}C NMR (126 MHz, DMSO) δ 152.24, 139.99, 139.48, 131.88, 129.65, 128.78, 126.67, 124.51, 121.75, 105.40, 81.45, 75.63, 35.71, 27.82, 19.83.

HRMS (ESI) m/z $[\text{M} + \text{H}]^+$ calculated for $\text{C}_{17}\text{H}_{21}\text{N}_3\text{O}_2$: 300.1707, found 300.1705.




methyl 1-(phenylsulfonyl)-2-(1H-pyrazol-1-yl)indoline-6-carboxylate (44):

^1H NMR (500 MHz, CDCl_3) δ 7.97 (d, $J = 3.2$ Hz, 1H), 7.68 (dd, $J = 7.9$, 3.1 Hz, 1H), 7.56 (d, $J = 3.2$ Hz, 1H), 7.50 – 7.36 (m, 3H), 7.33 (d, $J = 3.0$ Hz, 1H), 7.29 – 7.21 (m, 2H), 7.18 – 7.01 (m, 1H), 6.51 (dd, $J = 9.2$, 3.2 Hz, 1H), 6.11 (t, $J = 2.6$ Hz, 1H), 3.80 (d, $J = 2.6$ Hz, 3H), 3.48 (d, $J = 17.3$ Hz, 1H), 3.43 – 3.31 (m, 1H).

^{13}C NMR (126 MHz, CDCl_3) δ 166.58, 141.00, 140.90, 138.53, 134.72, 133.59, 130.57, 129.61, 129.28, 126.84, 126.37, 124.91, 115.28, 106.36, 75.58, 52.39, 35.99.

HRMS (ESI) m/z $[\text{M} + \text{H}]^+$ calculated for $\text{C}_{19}\text{H}_{17}\text{N}_3\text{O}_4\text{S}$: 384.1013, found 384.1010.




6-chloro-1-(phenylsulfonyl)-2-(1*H*-pyrazol-1-yl)indoline (45):

^1H NMR (500 MHz, CDCl_3) δ 7.65 (s, 1H), 7.53 (d, $J = 8.0$ Hz, 3H), 7.44 (d, $J = 3.8$ Hz, 2H), 7.38 (t, $J = 7.6$ Hz, 2H), 7.10 (d, $J = 8.0$ Hz, 1H), 7.03 (d, $J = 8.1$ Hz, 1H), 6.58 (d, $J = 8.2$ Hz, 1H), 6.21 (s, 1H), 3.74 – 3.04 (m, 2H).

^{13}C NMR (126 MHz, CDCl_3) δ 141.65, 141.01, 138.50, 133.90, 133.64, 129.56, 129.32, 127.79, 126.77, 125.79, 124.59, 114.99, 106.37, 75.88, 35.53.

HRMS (ESI) m/z $[\text{M} + \text{H}]^+$ calculated for $\text{C}_{17}\text{H}_{14}\text{ClN}_3\text{O}_2\text{S}$: 360.0568, found 360.0566.




4-methyl-1-(phenylsulfonyl)-2-(1*H*-pyrazol-1-yl)indoline (46):

^1H NMR (500 MHz, CDCl_3) δ 7.57 (d, $J = 2.5$ Hz, 1H), 7.50 – 7.45 (m, 2H), 7.43 – 7.32 (m, 2H), 7.32 – 7.19 (m, 3H), 7.04 (t, $J = 7.9$ Hz, 1H), 6.78 (d, $J = 7.6$ Hz, 1H), 6.49 (dd, $J = 9.0, 2.4$ Hz, 1H), 6.12 (t, $J = 2.1$ Hz, 1H), 3.34 (dd, $J = 16.9, 2.4$ Hz, 1H), 3.25 (dd, $J = 17.0, 9.0$ Hz, 1H), 2.08 (s, 3H).

^{13}C NMR (126 MHz, CDCl_3) δ 140.71, 140.16, 138.66, 134.75, 133.36, 129.26, 129.16, 128.33, 127.92, 126.87, 125.72, 112.20, 106.19, 75.56, 35.19, 18.80.

HRMS (ESI) m/z $[\text{M} + \text{H}]^+$ calculated for $\text{C}_{18}\text{H}_{17}\text{N}_3\text{O}_2\text{S}$: 340.1114, found 340.1111.




methyl 1-(phenylsulfonyl)-2-(1*H*-pyrazol-1-yl)indoline-5-carboxylate (47):

^1H NMR (500 MHz, CDCl_3) δ 7.85 (dd, $J = 8.5, 1.8$ Hz, 1H), 7.79 (d, $J = 1.7$ Hz, 1H), 7.55 (d, $J = 2.5$ Hz, 1H), 7.47 – 7.38 (m, 3H), 7.37 – 7.31 (m, 2H), 7.26 (t, $J = 7.8$ Hz, 2H), 6.56 (t, $J = 5.8$ Hz, 1H), 6.12 (t, $J = 2.1$ Hz, 1H), 3.78 (s, 3H), 3.48 (d, $J = 5.7$ Hz, 2H).

^{13}C NMR (126 MHz, CDCl_3) δ 166.54, 144.47, 141.07, 138.61, 133.61, 130.58, 129.74, 129.34, 129.23, 126.74, 126.52, 126.20, 113.40, 106.33, 75.69, 52.15, 35.63.

HRMS (ESI) m/z $[\text{M} + \text{H}]^+$ calculated for $\text{C}_{19}\text{H}_{17}\text{N}_3\text{O}_4\text{S}$: 384.1013, found 384.1012.




1-(phenylsulfonyl)-2-(1*H*-pyrazol-1-yl)indoline-4-carbaldehyde (48):

^1H NMR (500 MHz, CDCl_3) δ 10.04 (s, 1H), 7.68 (d, $J = 8.0$ Hz, 2H), 7.52 (dd, $J = 14.4, 7.7$ Hz, 4H), 7.48 – 7.41 (m, 2H), 7.37 (t, $J = 7.8$ Hz, 2H), 6.66 (d, $J = 9.3$ Hz, 1H), 6.23 (d, $J = 2.8$ Hz, 1H), 4.02 (d, $J = 18.7$ Hz, 1H), 3.76 (dd, $J = 18.8, 9.4$ Hz, 1H).

^{13}C NMR (126 MHz, CDCl_3) δ 192.11, 142.19, 141.26, 138.64, 133.67, 132.58, 130.47, 129.94, 129.33, 129.03, 128.34, 126.81, 119.39, 106.28, 75.94, 36.12.

HRMS (ESI) m/z $[\text{M} + \text{H}]^+$ calculated for $\text{C}_{18}\text{H}_{15}\text{N}_3\text{O}_3\text{S}$: 354.0907, found 354.0905.




***trans*-3-methyl-1-(phenylsulfonyl)-2-(1*H*-pyrazol-1-yl)indoline (49):**

^1H NMR (500 MHz, CDCl_3) δ 7.76 (dd, $J = 17.0, 8.0$ Hz, 3H), 7.66 (t, $J = 7.5$ Hz, 1H), 7.52 (dd, $J = 17.0, 9.3$ Hz, 3H), 7.45 (dd, $J = 11.4, 5.4$ Hz, 1H), 7.37 – 7.18 (m, 3H), 6.74 (d, $J = 8.2$ Hz, 1H), 6.27 (t, $J = 2.0$ Hz, 1H), 3.81 (p, $J = 7.6$ Hz, 1H), 1.07 (d, $J = 7.1$ Hz, 3H).

^{13}C NMR (126 MHz, CDCl_3) δ 140.77, 139.61, 138.74, 133.67, 133.29, 129.12, 128.41, 128.32, 126.92, 124.59, 123.84, 113.88, 106.15, 79.70, 41.31, 10.53.

HRMS (ESI) m/z $[\text{M} + \text{H}]^+$ calculated for $\text{C}_{18}\text{H}_{17}\text{N}_3\text{O}_2\text{S}$: 340.1114, found 340.1113.




***trans*-1-(phenylsulfonyl)-2-(1*H*-pyrazol-1-yl)indolin-3-yl acetate (50):**

^1H NMR (500 MHz, CDCl_3) δ 7.50 (d, $J = 7.9$ Hz, 3H), 7.39 (t, $J = 7.8$ Hz, 1H), 7.25 (q, $J = 9.8, 8.6$ Hz, 6H), 7.13 (d, $J = 7.7$ Hz, 1H), 7.01 (dt, $J = 7.6, 3.7$ Hz, 1H), 6.58 (dd, $J = 7.6, 2.6$ Hz, 1H), 6.12 (d, $J = 7.6$ Hz, 1H), 6.03 (s, 1H), 1.64 (d, $J = 2.7$ Hz, 3H).

^{13}C NMR (126 MHz, CDCl_3) δ 170.45, 140.65, 140.38, 138.02, 133.59, 130.68, 130.05, 129.21, 127.06, 126.72, 125.39, 124.72, 114.19, 106.00, 76.16, 72.68, 19.96.

HRMS (ESI) m/z $[\text{M} + \text{H}]^+$ calculated for $\text{C}_{19}\text{H}_{17}\text{N}_3\text{O}_4\text{S}$: 384.1013, found 384.1012.




methyl 2-1-(phenylsulfonyl)-2-(1*H*-pyrazol-1-yl)indolin-3-ylacetate (51):

^1H NMR (500 MHz, CDCl_3) δ 7.57 – 7.31 (m, 5H), 7.30 – 7.12 (m, 6H), 6.98 (q, $J = 8.6, 7.9$ Hz, 2H), 6.78 – 6.51 (m, 1H), 6.03 (s, 1H), 4.30 – 3.82 (m, 1H), 3.53 (d, $J = 2.4$ Hz, 3H), 2.61 (dd, $J = 17.5, 5.8$ Hz, 1H), 2.25 – 1.95 (m, 1H).

^{13}C NMR (126 MHz, CDCl_3) δ 172.38, 140.95, 140.78, 138.85, 133.28, 131.11, 130.26, 129.08, 128.76, 126.85, 124.32, 123.37, 113.71, 105.74, 77.94, 52.05, 42.53, 31.36.

HRMS (ESI) m/z $[\text{M} + \text{H}]^+$ calculated for $\text{C}_{20}\text{H}_{19}\text{N}_3\text{O}_4\text{S}$: 398.1169, found 398.1168.




Ethyl 1-(1-(phenylsulfonyl)indolin-2-yl)-1*H*-pyrazole-4-carboxylate (52):

^1H NMR (500 MHz, CDCl_3) δ 8.13 (d, $J = 0.6$ Hz, 1H), 7.84 (d, $J = 0.6$ Hz, 1H), 7.66 – 7.61 (m, 2H), 7.59 (d, $J = 8.1$ Hz, 1H), 7.56 – 7.49 (m, 1H), 7.43 – 7.35 (m, 2H), 7.32 – 7.25 (m, 1H), 7.17 (dd, $J = 7.5, 1.4$ Hz, 1H), 7.10 (td, $J = 7.5, 1.0$ Hz, 1H), 6.48 (dd, $J = 8.5, 2.3$ Hz, 1H), 4.27 (qd, $J = 7.1, 1.6$ Hz, 2H), 3.71 – 3.23 (m, 2H), 1.33 (t, $J = 7.1$ Hz, 3H).

^{13}C NMR (126 MHz, CDCl_3) δ 162.79, 142.10, 140.37, 138.26, 133.73, 132.17, 129.35, 128.98, 128.54, 126.87, 125.25, 125.23, 115.76, 115.49, 76.18, 60.42, 36.14, 14.52.

HRMS (ESI) m/z $[\text{M} + \text{H}]^+$ calculated for $\text{C}_{19}\text{H}_{17}\text{N}_3\text{O}_4\text{S}$: 384.1013, found 384.1012.




1-(1-(1-(phenylsulfonyl)indolin-2-yl)-1*H*-pyrazol-4-yl)ethan-1-one (53):

^1H NMR (500 MHz, CDCl_3) δ 8.00 (s, 1H), 7.71 (s, 1H), 7.61 – 7.50 (m, 2H), 7.47 (d, $J = 8.1$ Hz, 1H), 7.44 – 7.37 (m, 1H), 7.32 – 7.22 (m, 2H), 7.20 – 7.11 (m, 1H), 7.04 (d, $J = 8.0$ Hz, 1H), 6.97 (td, $J = 7.5, 0.9$ Hz, 1H), 6.36 (dd, $J = 8.6, 2.2$ Hz, 1H), 3.46 – 3.18 (m, 2H), 2.25 (s, 3H).

^{13}C NMR (126 MHz, CDCl_3) δ 191.94, 141.21, 140.27, 138.12, 133.77, 131.41, 129.35, 128.95, 128.54, 126.81, 125.31, 125.26, 124.47, 115.52, 76.23, 36.04, 28.06.

HRMS (ESI) m/z $[\text{M} + \text{H}]^+$ calculated for $\text{C}_{19}\text{H}_{17}\text{N}_3\text{O}_3\text{S}$: 368.1063, found 368.1061.




1-(1-(phenylsulfonyl)indolin-2-yl)-1H-pyrazole-4-carbaldehyde (54):

^1H NMR (500 MHz, CDCl_3) δ 9.67 (s, 1H), 8.08 (s, 1H), 7.77 (s, 1H), 7.57 – 7.50 (m, 2H), 7.47 (d, J = 8.1 Hz, 1H), 7.45 – 7.38 (m, 1H), 7.26 (t, J = 8.0 Hz, 2H), 7.19 – 7.09 (m, 1H), 7.03 (d, J = 8.0 Hz, 1H), 6.97 (td, J = 7.5, 1.0 Hz, 1H), 6.37 (dd, J = 8.6, 2.1 Hz, 1H), 3.35 (dd, J = 17.2, 2.1 Hz, 1H), 3.27 (dd, J = 17.1, 8.6 Hz, 1H).

^{13}C NMR (126 MHz, CDCl_3) δ 184.02, 141.11, 140.21, 138.05, 133.87, 132.89, 129.42, 128.88, 128.61, 126.83, 125.41, 125.31, 124.54, 115.56, 76.36, 36.06.

HRMS (ESI) m/z $[\text{M} + \text{H}]^+$ calculated for $\text{C}_{18}\text{H}_{15}\text{N}_3\text{O}_3\text{S}$: 354.0907, found 354.0905.




2-(4-methyl-1H-pyrazol-1-yl)-1-(phenylsulfonyl)indoline (55):

^1H NMR (500 MHz, CDCl_3) δ 7.58 (dd, J = 8.5, 1.3 Hz, 2H), 7.55 – 7.47 (m, 2H), 7.44 – 7.32 (m, 3H), 7.25 – 7.20 (m, 2H), 7.18 (d, J = 7.5 Hz, 1H), 7.11 – 7.02 (m, 1H), 6.47 (dd, J = 8.8, 2.2 Hz, 1H), 3.73 – 3.21 (m, 2H), 1.99 (s, 3H).

^{13}C NMR (126 MHz, CDCl_3) δ 141.18, 140.59, 138.80, 133.36, 129.51, 129.14, 128.25, 127.67, 126.92, 125.15, 124.73, 116.98, 115.06, 75.67, 35.96, 8.92.

HRMS (ESI) m/z $[\text{M} + \text{H}]^+$ calculated for $\text{C}_{18}\text{H}_{17}\text{N}_3\text{O}_2\text{S}$: 340.1114, found 340.1114.




2-(4-iodo-1H-pyrazol-1-yl)-1-(phenylsulfonyl)indoline (56):

^1H NMR (500 MHz, CDCl_3) δ 7.51 – 7.35 (m, 5H), 7.30 – 7.20 (m, 3H), 7.18 – 7.08 (m, 1H), 7.03 (dd, J = 7.6, 1.4 Hz, 1H), 6.94 (td, J = 7.5, 1.0 Hz, 1H), 6.35 (dd, J = 8.3, 2.5 Hz, 1H), 3.37 – 3.12 (m, 2H).

^{13}C NMR (126 MHz, CDCl_3) δ 145.33, 140.35, 138.33, 133.61, 133.28, 129.23, 128.99, 128.40, 126.73, 125.18, 124.95, 115.09, 75.95, 57.57, 35.89.

HRMS (ESI) m/z $[\text{M} + \text{H}]^+$ calculated for $\text{C}_{17}\text{H}_{14}\text{IN}_3\text{O}_2\text{S}$: 451.9924, found 451.9922.




2-(4-bromo-1H-pyrazol-1-yl)-1-(phenylsulfonyl)indoline (57):

^1H NMR (500 MHz, CDCl_3) δ 7.58 – 7.49 (m, 3H), 7.48 – 7.38 (m, 2H), 7.32 – 7.23 (m, 2H), 7.21 – 7.11 (m, 1H), 7.06 (dd, $J = 7.2, 1.4$ Hz, 1H), 6.97 (td, $J = 7.5, 1.0$ Hz, 1H), 6.35 (dd, $J = 8.6, 2.1$ Hz, 1H), 3.36 (dd, $J = 17.1, 2.2$ Hz, 1H), 3.28 (dd, $J = 17.1, 8.6$ Hz, 1H).

^{13}C NMR (126 MHz, CDCl_3) δ 140.91, 140.32, 138.31, 133.62, 129.24, 129.04, 129.02, 128.40, 126.76, 125.17, 125.00, 115.19, 94.25, 76.17, 35.79.

HRMS (ESI) m/z $[\text{M} + \text{H}]^+$ calculated for $\text{C}_{17}\text{H}_{14}\text{BrN}_3\text{O}_2\text{S}$: 404.0063, found 404.0062.




2-(4-chloro-1H-pyrazol-1-yl)-1-(phenylsulfonyl)indoline (58):

^1H NMR (500 MHz, CDCl_3) δ 7.61 – 7.38 (m, 5H), 7.38 – 7.23 (m, 3H), 7.22 – 7.14 (m, 1H), 7.09 (d, $J = 7.5$ Hz, 1H), 7.00 (t, $J = 7.5$ Hz, 1H), 6.35 (dd, $J = 8.6, 2.1$ Hz, 1H), 3.39 (dd, $J = 17.1, 2.0$ Hz, 1H), 3.29 (dd, $J = 17.0, 8.6$ Hz, 1H).

^{13}C NMR (126 MHz, CDCl_3) δ 140.34, 138.88, 138.36, 133.64, 129.27, 129.08, 128.44, 126.87, 126.80, 125.18, 125.04, 115.27, 111.06, 76.27, 35.76.

HRMS (ESI) m/z $[\text{M} + \text{H}]^+$ calculated for $\text{C}_{17}\text{H}_{14}\text{ClN}_3\text{O}_2\text{S}$: 360.0568, found 360.0566.




2-(4-fluoro-1H-pyrazol-1-yl)-1-(phenylsulfonyl)indoline (59):

^1H NMR (500 MHz, CDCl_3) δ 7.51 (dd, $J = 8.1, 1.5$ Hz, 2H), 7.46 – 7.34 (m, 3H), 7.26 (t, $J = 7.8$ Hz, 2H), 7.20 – 7.09 (m, 2H), 7.04 (d, $J = 7.5$ Hz, 1H), 6.95 (t, $J = 7.5$ Hz, 1H), 6.27 (dd, $J = 8.9, 2.0$ Hz, 1H), 3.36 (dd, $J = 17.1, 2.1$ Hz, 1H), 3.23 (dd, $J = 17.0, 8.8$ Hz, 1H).

^{13}C NMR (126 MHz, CDCl_3) δ 150.90, 148.93, 140.34, 138.43, 133.59, 129.25, 128.35, 127.69 (d, $J = 14.1$ Hz), 126.82, 125.12, 125.01, 115.36, 114.88 (d, $J = 28.0$ Hz), 76.59, 35.48.

HRMS (ESI) m/z $[\text{M} + \text{H}]^+$ calculated for $\text{C}_{17}\text{H}_{14}\text{FN}_3\text{O}_2\text{S}$: 344.0864, found 344.0863.



1-(phenylsulfonyl)-2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl)indoline (60):

^1H NMR (500 MHz, CDCl_3) δ 7.81 (s, 1H), 7.62 (s, 1H), 7.52 – 7.48 (m, 2H), 7.46 (d, J = 8.1 Hz, 1H), 7.43 – 7.37 (m, 1H), 7.26 (t, J = 7.9 Hz, 2H), 7.16 (dd, J = 8.1, 6.8 Hz, 1H), 7.06 (dd, J = 7.4, 1.4 Hz, 1H), 6.98 (td, J = 7.5, 1.0 Hz, 1H), 6.45 (t, J = 5.5 Hz, 1H), 3.32 (d, J = 5.5 Hz, 2H), 1.20 (s, 12H).

^{13}C NMR (126 MHz, CDCl_3) δ 146.47, 140.57, 138.52, 135.59, 133.44, 129.19, 129.15, 128.33, 126.87, 125.22, 124.89, 115.24, 83.49, 75.69, 36.40, 24.98, 24.94, 24.92, 24.82.

HRMS (ESI) m/z $[\text{M} + \text{H}]^+$ calculated for $\text{C}_{23}\text{H}_{26}\text{BN}_3\text{O}_4\text{S}$: 452.1810, found 452.1809.




1-(1-(phenylsulfonyl)indolin-2-yl)-1H-pyrazole-4-carbonitrile (61):

^1H NMR (500 MHz, CDCl_3) δ 7.81 (s, 1H), 7.62 (s, 1H), 7.40 (s, 1H), 7.32 (d, J = 7.6 Hz, 2H), 7.29 – 7.19 (m, 1H), 7.09 (t, J = 7.8 Hz, 2H), 6.96 (t, J = 7.8 Hz, 1H), 6.84 (d, J = 7.5 Hz, 1H), 6.78 (t, J = 7.5 Hz, 1H), 6.17 (dd, J = 8.6, 2.2 Hz, 1H), 3.22 – 2.98 (m, 2H).

^{13}C NMR (126 MHz, CDCl_3) δ 143.08, 139.95, 138.18, 137.71, 134.25, 134.03, 129.48, 128.68, 126.76, 125.52, 125.29, 115.52, 113.07, 92.99, 76.42, 35.91.

HRMS (ESI) m/z $[\text{M} + \text{H}]^+$ calculated for $\text{C}_{18}\text{H}_{14}\text{N}_4\text{O}_2\text{S}$: 351.0910, found 351.0909.




1-(1-(phenylsulfonyl)indolin-2-yl)-1H-pyrazole-4-(trifluoromethyl) (62):

^1H NMR (500 MHz, CDCl_3) δ 7.81 (s, 1H), 7.58 – 7.35 (m, 5H), 7.27 (d, J = 8.2 Hz, 2H), 7.15 (q, J = 7.5, 6.4 Hz, 1H), 7.06 (d, J = 7.5 Hz, 1H), 7.02 – 6.87 (m, 1H), 6.57 – 6.06 (m, 1H), 3.52 – 3.14 (m, 2H).

^{13}C NMR (126 MHz, CDCl_3) δ 140.33, 138.29, 137.98 (d, J = 2.7 Hz), 133.79, 129.37, 128.89, 128.59, 128.40 (d, J = 3.7 Hz), 126.76, 125.25 (d, J = 4.8 Hz), 122.41 (q, J = 266.2 Hz), 115.35, 114.30 (q, J = 38.1 Hz), 76.21, 36.06.

HRMS (ESI) m/z $[M + H]^+$ calculated for $C_{18}H_{14}F_3N_3O_2S$: 394.0832, found 394.0831.




2-(3-(*tert*-butyl)-1*H*-pyrazol-1-yl)-1-(phenylsulfonyl)indoline (63):

1H NMR (500 MHz, $CDCl_3$) δ 7.57 (d, $J = 7.8$ Hz, 2H), 7.50 (dd, $J = 9.8, 7.5$ Hz, 2H), 7.42 (t, $J = 2.0$ Hz, 1H), 7.38 – 7.31 (m, 2H), 7.23 (t, $J = 7.8$ Hz, 1H), 7.15 (d, $J = 7.5$ Hz, 1H), 7.05 (t, $J = 7.4$ Hz, 1H), 6.54 (dt, $J = 8.6, 2.1$ Hz, 1H), 6.01 (t, $J = 2.0$ Hz, 1H), 3.46 (d, $J = 16.8$ Hz, 1H), 3.38 (dd, $J = 17.0, 8.7$ Hz, 1H), 1.24 (d, $J = 1.8$ Hz, 9H).

^{13}C NMR (126 MHz, $CDCl_3$) δ 162.76, 140.70, 138.87, 133.30, 129.69, 129.13, 128.61, 128.03, 126.90, 125.18, 124.52, 115.00, 102.69, 75.91, 36.45, 32.27, 30.62.

HRMS (ESI) m/z $[M + H]^+$ calculated for $C_{21}H_{23}N_3O_2S$: 382.1583, found 392.1582.




2-(4-bromo-3-methyl-1*H*-pyrazol-1-yl)-1-(phenylsulfonyl)indoline (64):

1H NMR (500 MHz, $CDCl_3$) δ 7.63 (dtd, $J = 54.0, 11.1, 9.9, 5.3$ Hz, 5H), 7.43 (dt, $J = 8.3, 5.0$ Hz, 2H), 7.32 (q, $J = 9.9$ Hz, 1H), 7.29 – 7.19 (m, 1H), 7.14 (td, $J = 7.5, 3.0$ Hz, 1H), 6.52 (dd, $J = 66.8, 8.9$ Hz, 1H), 3.98 – 3.10 (m, 2H), 2.32 (dd, $J = 148.6, 3.3$ Hz, 3H).

^{13}C NMR (126 MHz, $CDCl_3$) δ 148.38, 140.71 (d, $J = 45.1$ Hz), 139.58 (d, $J = 210.1$ Hz), 138.08 (d, $J = 72.2$ Hz), 133.44 (d, $J = 21.1$ Hz), 129.13 (d, $J = 7.3$ Hz), 128.98 (d, $J = 16.3$ Hz), 128.26 (d, $J = 20.5$ Hz), 126.69 (d, $J = 25.7$ Hz), 124.79 (d, $J = 14.5$ Hz), 124.78 (d, $J = 119.9$ Hz), 114.60 (d, $J = 146.3$ Hz), 94.78 (d, $J = 63.7$ Hz), 74.63 (d, $J = 385.2$ Hz), 36.16 (d, $J = 52.5$ Hz), 10.94 (d, $J = 276.0$ Hz).

HRMS (ESI) m/z $[M + H]^+$ calculated for $C_{18}H_{16}BrN_3O_2S$: 418.0219, found 418.0217.




2-(3,5-dimethyl-1*H*-pyrazol-1-yl)-1-(phenylsulfonyl)indoline (65):

1H NMR (500 MHz, $CDCl_3$) δ 7.61 – 7.50 (m, 2H), 7.46 (dd, $J = 7.8, 6.4$ Hz, 2H), 7.33 (t, $J = 7.9$ Hz, 2H), 7.25 – 7.18 (m, 1H), 7.16 (dd, $J = 7.5, 1.4$ Hz, 1H), 7.03 (td, $J = 7.5, 1.0$ Hz, 1H), 6.48 (dd, $J = 9.8, 3.1$ Hz, 1H), 5.70 (s, 1H), 3.52 (dd, $J = 16.8, 9.8$ Hz, 1H), 3.34 (dd, $J = 16.8, 3.1$ Hz, 1H), 2.36 (s, 3H), 1.99 (s, 3H).

^{13}C NMR (126 MHz, CDCl_3) δ 149.15, 141.13, 140.12, 139.09, 132.99, 129.05, 128.81, 127.87, 126.83, 124.81, 123.73, 113.76, 106.06, 72.20, 36.45, 13.68, 11.10.

HRMS (ESI) m/z $[\text{M} + \text{H}]^+$ calculated for $\text{C}_{19}\text{H}_{19}\text{N}_3\text{O}_2\text{S}$: 354.1271, found 354.1269.




2-(4-bromo-3,5-dimethyl-1H-pyrazol-1-yl)-1-(phenylsulfonyl)indoline (66):

^1H NMR (500 MHz, CDCl_3) δ 7.43 (dt, $J = 20.8, 7.9$ Hz, 4H), 7.26 (t, $J = 7.8$ Hz, 2H), 7.17 (t, $J = 7.8$ Hz, 1H), 7.09 (d, $J = 7.4$ Hz, 1H), 6.97 (t, $J = 7.5$ Hz, 1H), 6.39 (dd, $J = 9.7, 2.8$ Hz, 1H), 3.46 (dd, $J = 16.9, 9.8$ Hz, 1H), 3.22 (dd, $J = 16.9, 2.9$ Hz, 1H), 2.25 (s, 3H), 1.85 (s, 3H).

^{13}C NMR (126 MHz, CDCl_3) δ 147.57, 141.16, 138.83, 138.03, 133.15, 128.79, 128.76, 128.07, 126.61, 124.82, 123.90, 113.72, 95.66, 73.07, 36.29, 12.40, 10.43.

HRMS (ESI) m/z $[\text{M} + \text{H}]^+$ calculated for $\text{C}_{19}\text{H}_{18}\text{BrN}_3\text{O}_2\text{S}$: 432.0376, found 432.0375.



2-(1H-imidazol-1-yl)-1-(phenylsulfonyl)indoline (67):

^1H NMR (500 MHz, CDCl_3) δ 7.53 (s, 1H), 7.41 (d, $J = 8.0$ Hz, 3H), 7.36 (d, $J = 8.1$ Hz, 1H), 7.26 (t, $J = 7.7$ Hz, 2H), 7.16 (dd, $J = 9.3, 6.4$ Hz, 1H), 7.10 (d, $J = 7.5$ Hz, 1H), 6.98 (t, $J = 7.5$ Hz, 1H), 6.80 (s, 1H), 6.59 (s, 1H), 6.37 (d, $J = 8.9$ Hz, 1H), 3.47 (dd, $J = 17.2, 9.0$ Hz, 1H), 3.02 (d, $J = 17.1$ Hz, 1H).

^{13}C NMR (126 MHz, CDCl_3) δ 140.11, 138.52, 136.10, 133.57, 130.44, 129.33, 128.74, 127.97, 126.69, 125.26, 124.68, 116.01, 114.58, 71.69, 37.18.

HRMS (ESI) m/z $[\text{M} + \text{H}]^+$ calculated for $\text{C}_{17}\text{H}_{15}\text{N}_3\text{O}_2\text{S}$: 181.0972, found 181.0970.




1-(phenylsulfonyl)-2-(1H-1,2,3-triazol-1-yl)indoline (68):

^1H NMR (500 MHz, CDCl_3) δ 7.76 (d, $J = 1.1$ Hz, 1H), 7.66 (dd, $J = 8.2, 1.5$ Hz, 2H), 7.62 (d, $J = 8.0$ Hz, 2H), 7.59 – 7.50 (m, 1H), 7.42 (t, $J = 7.8$ Hz, 2H), 7.29 (t, $J = 7.8$ Hz, 1H), 7.19 (d, $J = 7.5$ Hz, 1H), 7.12 (t, $J = 7.5$ Hz, 1H), 6.77 (dd, $J = 8.7, 1.7$ Hz, 1H), 3.66 – 3.59 (m, 1H), 3.43 (dd, $J = 17.2, 8.7$ Hz, 1H).

^{13}C NMR (126 MHz, CDCl_3) δ 140.07, 137.90, 134.27, 133.95, 129.52, 129.00, 128.72, 126.91, 125.60, 125.45, 122.57, 116.04, 74.97, 36.23.

HRMS (ESI) m/z $[\text{M} + \text{H}]^+$ calculated for $\text{C}_{17}\text{H}_{15}\text{N}_4\text{O}_2\text{S}$: 327.0910, found 327.0908.




1-(phenylsulfonyl)-2-(1H-1,2,4-triazol-1-yl)indoline (69):

^1H NMR (500 MHz, CDCl_3) δ 8.25 (s, 1H), 7.70 (s, 1H), 7.57 – 7.46 (m, 2H), 7.45 – 7.37 (m, 2H), 7.26 (t, $J = 7.9$ Hz, 2H), 7.13 (t, $J = 7.8$ Hz, 1H), 7.04 (d, $J = 7.5$ Hz, 1H), 6.96 (t, $J = 7.4$ Hz, 1H), 6.45 (dd, $J = 8.1, 2.7$ Hz, 1H), 3.48 – 3.13 (m, 2H).

^{13}C NMR (126 MHz, CDCl_3) δ 152.53, 143.13, 140.06, 138.07, 133.75, 129.35, 128.70, 128.48, 126.67, 125.18, 125.14, 115.25, 73.91, 35.74.

HRMS (ESI) m/z $[\text{M} + \text{H}]^+$ calculated for $\text{C}_{17}\text{H}_{15}\text{N}_4\text{O}_2\text{S}$: 327.0910, found 327.0910.



2-(5-methyl-1H-tetrazol-1-yl)-1-(phenylsulfonyl)indoline (70):


^1H NMR (500 MHz, CDCl_3) δ 7.66 (dd, $J = 21.4, 7.9$ Hz, 3H), 7.54 (t, $J = 7.7$ Hz, 1H), 7.39 (t, $J = 7.7$ Hz, 2H), 7.31 (t, $J = 7.9$ Hz, 1H), 7.21 (d, $J = 7.5$ Hz, 1H), 7.12 (t, $J = 7.5$ Hz, 1H), 7.04 (d, $J = 9.1$ Hz, 1H), 3.60 (dd, $J = 17.3, 9.2$ Hz, 1H), 3.34 (d, $J = 17.1$ Hz, 1H), 2.36 (d, $J = 2.6$ Hz, 3H).

^{13}C NMR (126 MHz, CDCl_3) δ 163.66, 140.60, 138.20, 133.70, 129.28, 128.64, 128.06, 126.89, 125.12, 124.95, 115.00, 76.29, 36.11, 10.97.

^1H NMR (500 MHz, CDCl_3) δ 7.86 – 7.51 (m, 4H), 7.42 (t, $J = 7.8$ Hz, 2H), 7.30 (t, $J = 8.0$ Hz, 1H), 7.20 (d, $J = 7.6$ Hz, 1H), 7.15 (d, $J = 7.7$ Hz, 1H), 6.69 (d, $J = 8.9$ Hz, 1H), 3.54 (dd, $J = 17.3, 9.2$ Hz, 1H), 3.34 (d, $J = 17.2$ Hz, 1H), 2.66 (s, 3H).

^{13}C NMR (126 MHz, CDCl_3) δ 151.59, 139.90, 137.46, 134.12, 129.53, 128.76, 128.36, 126.67, 125.51, 125.02, 115.46, 72.25, 36.49, 9.36.

HRMS (ESI) m/z $[\text{M} + \text{H}]^+$ calculated for $\text{C}_{16}\text{H}_{15}\text{N}_5\text{O}_2\text{S}$: 342.1019, found 342.1018.




1-(1-(phenylsulfonyl)indolin-2-yl)-1*H*-benzo[d]imidazole (71):

¹H NMR (500 MHz, CDCl₃) δ 7.86 (s, 1H), 7.58 (d, *J* = 8.1 Hz, 1H), 7.49 (d, *J* = 8.1 Hz, 1H), 7.26 (t, *J* = 7.0 Hz, 3H), 7.21 – 7.11 (m, 2H), 7.02 (dt, *J* = 23.5, 7.6 Hz, 4H), 6.86 (t, *J* = 7.7 Hz, 1H), 6.66 (dd, *J* = 10.1, 2.7 Hz, 1H), 6.55 (d, *J* = 8.2 Hz, 1H), 3.62 (dd, *J* = 17.4, 9.9 Hz, 1H), 3.19 (dd, *J* = 17.4, 2.6 Hz, 1H).

¹³C NMR (126 MHz, CDCl₃) δ 144.30, 142.36, 140.75, 138.15, 133.34, 131.27, 128.99, 128.94, 127.82, 126.20, 125.17, 124.65, 123.49, 122.74, 120.67, 114.05, 110.86, 71.61, 35.78.

HRMS (ESI) *m/z* [M + H]⁺ calculated for C₂₁H₁₇N₃O₂S: 376.1114, found 376.1112.




1-(1-(phenylsulfonyl)indolin-2-yl)-1*H*-indazole (72):

¹H NMR (500 MHz, CDCl₃) δ 8.16 (s, 1H), 7.66 (d, *J* = 8.1 Hz, 1H), 7.58 (dt, *J* = 16.7, 8.9 Hz, 4H), 7.43 (t, *J* = 7.4 Hz, 1H), 7.26 (q, *J* = 13.2, 11.4, 8.1 Hz, 4H), 7.16 (d, *J* = 7.4 Hz, 1H), 7.10 (t, *J* = 7.5 Hz, 1H), 7.03 (t, *J* = 7.6 Hz, 1H), 6.79 (dd, *J* = 8.7, 2.4 Hz, 1H), 3.58 (d, *J* = 17.0 Hz, 1H), 3.49 (dd, *J* = 17.2, 8.6 Hz, 1H).

¹³C NMR (126 MHz, CDCl₃) δ 149.25, 140.69, 138.08, 133.60, 129.27, 129.12, 128.46, 126.84, 126.62, 125.43, 125.16, 122.16, 122.06, 121.67, 120.67, 117.86, 115.49, 77.35, 37.06.

HRMS (ESI) *m/z* [M + H]⁺ calculated for C₂₁H₁₇N₃O₂S: 376.1114, found 376.1114.




1-(1-(phenylsulfonyl)indolin-2-yl)-1*H*-benzo[d][1,2,3]triazole (73):

¹H NMR (500 MHz, Chloroform-*d*) δ 8.01 (dd, *J* = 6.3, 3.2 Hz, 1H), 7.73 (d, *J* = 8.1 Hz, 1H), 7.58 (d, *J* = 7.8 Hz, 2H), 7.42 (q, *J* = 8.0 Hz, 2H), 7.37 – 7.19 (m, 8H), 7.17 (dd, *J* = 6.5, 3.2 Hz, 1H), 3.73 (dd, *J* = 17.3, 9.6 Hz, 1H), 3.51 (dd, *J* = 17.4, 2.7 Hz, 1H).

¹³C NMR (126 MHz, CDCl₃) δ 146.48, 140.71, 137.82, 133.48, 131.20, 129.04, 128.81, 128.75, 127.92, 126.53, 125.11, 125.07, 124.26, 120.04, 115.12, 110.51, 74.16, 35.97.

HRMS (ESI) *m/z* [M + H]⁺ calculated for C₂₀H₁₆N₄O₂S: 377.1067, found 377.1065.




***N*-benzyl-1-(phenylsulfonyl)indolin-2-amine (74):**

^1H NMR (500 MHz, Chloroform-*d*) δ 7.68 – 7.47 (m, 3H), 7.42 (t, J = 7.6 Hz, 1H), 7.34 – 7.19 (m, 6H), 7.16 (tq, J = 6.3, 2.1, 1.6 Hz, 2H), 7.02 – 6.80 (m, 2H), 5.24 (dd, J = 8.6, 2.5 Hz, 1H), 3.86 (q, J = 13.3 Hz, 2H), 2.85 (dd, J = 17.0, 8.7 Hz, 1H), 2.67 (dd, J = 16.9, 2.5 Hz, 1H), 2.30 (s, 1H).

^{13}C NMR (126 MHz, CDCl_3) δ 140.56, 139.92, 138.67, 133.09, 131.31, 129.11, 128.48, 128.39, 128.03, 127.10, 126.91, 125.09, 124.80, 117.33, 78.49, 47.53, 35.21.

HRMS (ESI) m/z $[\text{M} + \text{H}]^+$ calculated for $\text{C}_{21}\text{H}_{20}\text{N}_2\text{O}_2\text{S}$: 365.1318, found 365.1317.




1-(phenylsulfonyl)-*N*-(pyridin-2-ylmethyl)indolin-2-amine (75):

^1H NMR (500 MHz, CDCl_3) δ 8.42 (dd, J = 5.0, 1.8 Hz, 1H), 7.64 – 7.47 (m, 4H), 7.39 (t, J = 7.5 Hz, 1H), 7.26 (t, J = 7.8 Hz, 2H), 7.18 (d, J = 7.8 Hz, 1H), 7.15 – 7.08 (m, 1H), 7.04 (dd, J = 7.6, 4.9 Hz, 1H), 6.95 (dt, J = 14.6, 7.3 Hz, 2H), 5.28 (dd, J = 8.5, 2.2 Hz, 1H), 4.33 – 3.69 (m, 2H), 2.82 (dd, J = 16.9, 8.4 Hz, 2H), 2.68 (dd, J = 17.0, 2.3 Hz, 1H).

^{13}C NMR (126 MHz, CDCl_3) δ 158.97, 149.23, 140.33, 138.61, 136.37, 132.96, 131.45, 128.98, 127.88, 126.78, 125.00, 124.80, 122.40, 121.89, 117.55, 78.33, 48.98, 35.33.

HRMS (ESI) m/z $[\text{M} + \text{H}]^+$ calculated for $\text{C}_{20}\text{H}_{19}\text{N}_3\text{O}_2\text{S}$: 366.1271, found 366.1270.




1-(phenylsulfonyl)-*N*-(thiophen-2-ylmethyl)indolin-2-amine (76):

^1H NMR (500 MHz, CDCl_3) δ 7.98 – 7.80 (m, 3H), 7.71 (t, J = 7.4 Hz, 1H), 7.58 (t, J = 7.7 Hz, 2H), 7.49 – 7.43 (m, 1H), 7.40 (dd, J = 5.1, 1.3 Hz, 1H), 7.25 (d, J = 6.9 Hz, 2H), 7.21 – 7.01 (m, 2H), 5.50 (dd, J = 8.6, 2.3 Hz, 1H), 4.41 (d, J = 14.1 Hz, 1H), 4.33 (d, J = 14.1 Hz, 1H), 3.11 (dd, J = 17.0, 8.6 Hz, 1H), 2.94 (dd, J = 17.0, 2.3 Hz, 1H), 2.68 (s, 1H).

^{13}C NMR (126 MHz, CDCl_3) δ 143.59, 140.40, 138.56, 133.14, 131.39, 129.13, 128.08, 126.91, 126.78, 125.25, 125.12, 124.97, 124.58, 117.65, 78.00, 42.88, 35.36.

HRMS (ESI) m/z $[\text{M} + \text{H}]^+$ calculated for $\text{C}_{19}\text{H}_{18}\text{N}_2\text{O}_2\text{S}_2$: 371.0882, found 371.0881.




1-(phenylsulfonyl)-*N*-(prop-2-yn-1-yl)indolin-2-amine (77):

^1H NMR (500 MHz, CDCl_3) δ 7.85 (dd, $J = 7.9, 2.2$ Hz, 3H), 7.71 (t, $J = 7.5$ Hz, 1H), 7.58 (t, $J = 7.7$ Hz, 2H), 7.51 – 7.41 (m, 1H), 7.25 (d, $J = 7.0$ Hz, 2H), 5.42 (d, $J = 8.3$ Hz, 1H), 4.10 – 3.65 (m, 2H), 3.07 (dd, $J = 17.0, 8.4$ Hz, 1H), 2.90 (dd, $J = 17.0, 2.2$ Hz, 1H), 2.46 (s, 1H).

^{13}C NMR (126 MHz, CDCl_3) δ 140.27, 138.45, 133.23, 131.25, 129.17, 128.17, 126.93, 125.17, 125.13, 117.81, 86.19, 81.74, 71.35, 35.37, 33.46.

HRMS (ESI) m/z $[\text{M} + \text{H}]^+$ calculated for $\text{C}_{17}\text{H}_{16}\text{N}_2\text{O}_2\text{S}$: 313.1005, found 313.1003.




1-(phenylsulfonyl)indolin-2-yl acetate (78):

^1H NMR (500 MHz, CDCl_3) δ 7.91 (dd, $J = 8.4, 1.3$ Hz, 2H), 7.70 – 7.56 (m, 2H), 7.50 (t, $J = 7.9$ Hz, 2H), 7.35 – 7.23 (m, 1H), 7.18 (d, $J = 7.4$ Hz, 1H), 7.12 – 7.01 (m, 1H), 6.86 (dd, $J = 7.0, 1.2$ Hz, 1H), 3.34 (dd, $J = 17.5, 7.0$ Hz, 1H), 2.94 (d, $J = 17.5$ Hz, 1H), 2.02 (s, 3H).

^{13}C NMR (126 MHz, CDCl_3) δ 169.76, 140.62, 139.26, 133.55, 129.30, 128.53, 128.24, 127.17, 125.31, 124.29, 114.49, 85.81, 36.98, 21.11.

HRMS (ESI) m/z $[\text{M} + \text{H}]^+$ calculated for $\text{C}_{16}\text{H}_{15}\text{NO}_4\text{S}$: 318.0795, found 318.0794.




5-methyl-1-(phenylsulfonyl)indolin-2-yl acetate (79):

^1H NMR (500 MHz, CDCl_3) δ 7.66 (d, $J = 7.9$ Hz, 2H), 7.36 (d, $J = 8.0$ Hz, 1H), 7.26 (t, $J = 7.5$ Hz, 3H), 6.85 (d, $J = 8.2$ Hz, 1H), 6.76 (s, 1H), 6.59 (d, $J = 6.8$ Hz, 1H), 3.04 (dd, $J = 17.5, 6.9$ Hz, 1H), 2.65 (d, $J = 17.5$ Hz, 1H), 2.09 (s, 3H), 1.80 (s, 3H).

^{13}C NMR (126 MHz, CDCl_3) δ 169.81, 139.17, 138.26, 134.18, 133.46, 129.27, 128.73, 127.15, 126.82, 125.95, 114.45, 86.05, 36.96, 21.13, 21.02.

HRMS (ESI) m/z $[\text{M} + \text{H}]^+$ calculated for $\text{C}_{17}\text{H}_{17}\text{NO}_4\text{S}$: 332.0951, found 332.0949.




1-(phenylsulfonyl)indolin-2-yl 2-cyclopropylacetate (80):

^1H NMR (500 MHz, CDCl_3) δ 7.72 – 7.57 (m, 2H), 7.36 (td, $J = 7.8, 4.9$ Hz, 2H), 7.26 (t, $J = 7.9$ Hz, 2H), 7.04 (t, $J = 7.7$ Hz, 1H), 6.95 (d, $J = 7.4$ Hz, 1H), 6.84 (t, $J = 7.5$ Hz, 1H), 6.65 (dd, $J = 7.0, 1.3$ Hz, 1H), 3.13 (dd, $J = 17.6, 7.1$ Hz, 1H), 2.71 (d, $J = 17.5$ Hz, 1H), 1.95 (qd, $J = 16.0, 7.1$ Hz, 2H), 0.80 (tdd, $J = 10.3, 9.1, 5.1$ Hz, 1H), 0.33 (dd, $J = 8.1, 1.6$ Hz, 2H), -0.07 (dd, $J = 8.8, 4.9$ Hz, 2H).

^{13}C NMR (126 MHz, CDCl_3) δ 172.06, 140.65, 139.26, 133.53, 129.30, 128.57, 128.21, 127.17, 125.30, 124.26, 114.50, 85.69, 39.31, 37.09, 6.64, 4.47, 4.43.

HRMS (ESI) m/z $[\text{M} + \text{H}]^+$ calculated for $\text{C}_{19}\text{H}_{19}\text{NO}_4\text{S}$: 358.1108, found 358.1107.




1-(phenylsulfonyl)indolin-2-yl hex-5-ynoate (81):

^1H NMR (500 MHz, CDCl_3) δ 8.24 – 7.97 (m, 2H), 7.87 – 7.74 (m, 2H), 7.69 (t, $J = 7.7$ Hz, 2H), 7.55 – 7.40 (m, 1H), 7.36 (d, $J = 7.4$ Hz, 1H), 7.26 (t, $J = 7.5$ Hz, 1H), 7.06 (d, $J = 7.0$ Hz, 1H), 3.53 (dd, $J = 17.6, 7.1$ Hz, 1H), 3.12 (d, $J = 17.5$ Hz, 1H), 2.60 (td, $J = 7.4, 4.2$ Hz, 2H), 2.46 (td, $J = 6.9, 2.6$ Hz, 2H), 2.18 (t, $J = 2.7$ Hz, 1H), 2.03 (p, $J = 7.2$ Hz, 2H).

^{13}C NMR (126 MHz, CDCl_3) δ 171.89, 140.58, 139.18, 133.58, 129.33, 128.46, 128.24, 127.15, 125.31, 124.28, 114.44, 85.69, 83.21, 69.43, 36.99, 32.92, 23.32, 17.86.

HRMS (ESI) m/z $[\text{M} + \text{H}]^+$ calculated for $\text{C}_{20}\text{H}_{19}\text{NO}_4\text{S}$: 370.1108, found 370.1106.




1-(phenylsulfonyl)indolin-2-yl pent-4-enoate (82):

^1H NMR (500 MHz, CDCl_3) δ 7.67 (d, $J = 7.8$ Hz, 2H), 7.36 (d, $J = 7.7$ Hz, 2H), 7.26 (t, $J = 7.7$ Hz, 2H), 7.12 – 6.99 (m, 1H), 6.94 (d, $J = 7.4$ Hz, 1H), 6.84 (t, $J = 7.5$ Hz, 1H), 6.63 (d, $J = 6.9$ Hz, 1H), 5.81 – 5.46 (m, 1H), 4.96 – 4.59 (m, 2H), 3.11 (dd, $J = 17.5, 7.0$ Hz, 1H), 2.68 (d, $J = 17.5$ Hz, 1H), 2.13 (t, $J = 3.6$ Hz, 4H).

^{13}C NMR (126 MHz, CDCl_3) δ 171.86, 140.61, 139.21, 136.39, 133.55, 129.31, 128.52, 128.23, 127.15, 125.30, 124.28, 115.89, 114.48, 85.76, 37.04, 33.52, 28.62.

HRMS (ESI) m/z $[\text{M} + \text{H}]^+$ calculated for $\text{C}_{19}\text{H}_{19}\text{NO}_4\text{S}$: 357.1035, found 357.1033.




1-(phenylsulfonyl)indolin-2-yl 4-phenylbutanoate (83):

^1H NMR (500 MHz, CDCl_3) δ 8.05 – 7.86 (m, 2H), 7.77 – 7.58 (m, 2H), 7.52 (t, J = 7.9 Hz, 2H), 7.36 (dt, J = 14.5, 7.6 Hz, 3H), 7.32 – 7.27 (m, 1H), 7.25 (dd, J = 7.8, 2.3 Hz, 3H), 7.15 (t, J = 7.5 Hz, 1H), 6.95 (dd, J = 7.2, 1.2 Hz, 1H), 3.42 (dd, J = 17.5, 7.0 Hz, 1H), 2.98 (d, J = 17.5 Hz, 1H), 2.74 (t, J = 7.5 Hz, 2H), 2.34 (hept, J = 7.9, 7.4 Hz, 2H), 2.02 (p, J = 7.5 Hz, 2H).

^{13}C NMR (126 MHz, CDCl_3) δ 172.26, 141.31, 140.62, 139.24, 133.51, 129.28, 128.65, 128.54, 128.50, 128.23, 127.13, 126.14, 125.31, 124.26, 114.46, 85.67, 37.01, 35.09, 33.58, 26.27.

HRMS (ESI) m/z $[\text{M} + \text{H}]^+$ calculated for $\text{C}_{24}\text{H}_{23}\text{NO}_4\text{S}$: 422.1421, found 422.1420.




1-(phenylsulfonyl)indolin-2-yl 6-azido hexanoate (84):

^1H NMR (500 MHz, CDCl_3) δ 7.66 (dd, J = 7.7, 1.6 Hz, 2H), 7.45 – 7.33 (m, 2H), 7.26 (t, J = 7.8 Hz, 2H), 7.09 – 6.98 (m, 1H), 6.94 (d, J = 7.4 Hz, 1H), 6.84 (t, J = 7.5 Hz, 1H), 6.62 (dd, J = 7.2, 1.2 Hz, 1H), 3.11 (dd, J = 17.6, 7.1 Hz, 1H), 3.05 (t, J = 6.9 Hz, 2H), 2.68 (d, J = 17.5 Hz, 1H), 2.24 – 1.92 (m, 2H), 1.40 (dp, J = 20.0, 7.3 Hz, 4H), 1.29 – 1.13 (m, 2H).

^{13}C NMR (126 MHz, CDCl_3) δ 172.24, 140.59, 139.18, 133.56, 129.32, 128.49, 128.25, 127.13, 125.31, 124.31, 114.51, 85.64, 51.29, 37.01, 34.10, 28.60, 26.20, 24.22.

HRMS (ESI) m/z $[\text{M} + \text{H}]^+$ calculated for $\text{C}_{20}\text{H}_{22}\text{N}_4\text{O}_4\text{S}$: 415.1435, found 415.1433.




2-methoxy-1-(phenylsulfonyl)indoline (85):

^1H NMR (500 MHz, CDCl_3) δ 7.79 – 7.64 (m, 2H), 7.62 (d, J = 8.0 Hz, 1H), 7.55 – 7.43 (m, 1H), 7.37 (t, J = 7.9 Hz, 2H), 7.25 – 7.17 (m, 1H), 7.12 – 6.96 (m, 2H), 5.50 (dd, J = 4.9, 2.2 Hz, 1H), 3.51 (s, 3H), 2.90 – 2.64 (m, 2H).

^{13}C NMR (126 MHz, CDCl_3) δ 140.28, 138.91, 133.21, 131.62, 129.09, 127.87, 126.95, 125.20, 125.13, 117.69, 93.50, 55.22, 36.48.

HRMS (ESI) m/z $[\text{M} + \text{H}]^+$ calculated for $\text{C}_{15}\text{H}_{15}\text{NO}_3\text{S}$: 290.0845, found 290.0843.




2-ethoxy-1-(phenylsulfonyl)indoline (86):

^1H NMR (500 MHz, CDCl_3) δ 7.56 (d, $J = 7.9$ Hz, 2H), 7.50 (d, $J = 8.0$ Hz, 1H), 7.39 (t, $J = 7.5$ Hz, 1H), 7.26 (t, $J = 7.7$ Hz, 2H), 7.12 (t, $J = 7.7$ Hz, 1H), 6.95 (dt, $J = 14.8, 7.4$ Hz, 2H), 5.50 (dd, $J = 4.9, 2.5$ Hz, 1H), 3.87 (dq, $J = 10.0, 7.1$ Hz, 1H), 3.58 (dq, $J = 9.8, 6.9$ Hz, 1H), 2.66 (d, $J = 4.1$ Hz, 2H), 1.09 (t, $J = 7.0$ Hz, 3H).

^{13}C NMR (126 MHz, CDCl_3) δ 140.33, 138.97, 133.15, 131.76, 129.05, 127.78, 126.93, 125.16, 125.09, 117.62, 92.19, 63.31, 36.71, 14.93.

HRMS (ESI) m/z $[\text{M} + \text{H}]^+$ calculated for $\text{C}_{16}\text{H}_{17}\text{NO}_3\text{S}$: 304.1002, found 304.1001.




2-methoxy-5-methyl-1-(phenylsulfonyl)indoline (87):

^1H NMR (500 MHz, CDCl_3) δ 7.64 (dd, $J = 8.1, 1.5$ Hz, 2H), 7.50 (t, $J = 7.3$ Hz, 2H), 7.37 (t, $J = 7.7$ Hz, 2H), 7.03 (d, $J = 8.2$ Hz, 1H), 6.89 (s, 1H), 5.45 (dd, $J = 5.4, 1.6$ Hz, 1H), 3.51 (s, 3H), 3.04 – 2.53 (m, 2H), 2.27 (s, 3H).

^{13}C NMR (126 MHz, CDCl_3) δ 138.90, 137.86, 135.10, 133.13, 131.84, 129.08, 128.50, 126.97, 125.78, 117.71, 93.71, 55.24, 36.53, 21.16.

HRMS (ESI) m/z $[\text{M} + \text{H}]^+$ calculated for $\text{C}_{16}\text{H}_{17}\text{NO}_3\text{S}$: 304.1002, found 304.1002.




ethyl hydrogen (1-(phenylsulfonyl)indolin-2-yl)phosphonate (88):

^1H NMR (500 MHz, CDCl_3) δ 7.66 (d, $J = 7.7$ Hz, 2H), 7.60 (d, $J = 8.1$ Hz, 1H), 7.50 (t, $J = 7.6$ Hz, 1H), 7.36 (t, $J = 7.8$ Hz, 2H), 7.22 (t, $J = 7.7$ Hz, 1H), 7.06 (dt, $J = 14.7, 7.4$ Hz, 2H), 5.59 (dd, $J = 4.8, 2.3$ Hz, 1H), 4.25 – 3.83 (m, 1H), 3.68 (dq, $J = 8.8, 7.0$ Hz, 1H), 2.76 (d, $J = 4.9$ Hz, 2H), 1.19 (dd, $J = 8.0, 6.5$ Hz, 3H).

^{13}C NMR (126 MHz, CDCl_3) δ 140.32, 138.94, 133.16, 131.77, 129.06, 127.80, 126.93, 125.17, 125.12, 117.66, 92.20, 63.34, 36.72, 14.94.

HRMS (ESI) m/z $[M + H]^+$ calculated for $C_{16}H_{18}NO_5PS$: 368.0716, found 368.0715.




ethyl hydrogen (5-methyl-1-(phenylsulfonyl)indolin-2-yl)phosphonate (89):

1H NMR (500 MHz, $CDCl_3$) δ 7.77 – 7.59 (m, 2H), 7.56 – 7.43 (m, 2H), 7.36 (t, $J = 7.9$ Hz, 2H), 7.02 (dd, $J = 8.1, 1.8$ Hz, 1H), 6.88 (s, 1H), 5.55 (dd, $J = 5.2, 1.8$ Hz, 1H), 3.97 (dq, $J = 9.8, 7.1$ Hz, 1H), 3.67 (dq, $J = 9.7, 7.0$ Hz, 1H), 2.84 – 2.59 (m, 2H), 2.27 (s, 3H), 1.19 (t, $J = 7.0$ Hz, 3H).

^{13}C NMR (126 MHz, $CDCl_3$) δ 138.95, 137.93, 134.97, 133.07, 132.00, 129.03, 128.40, 126.95, 125.81, 117.64, 92.39, 63.28, 36.72, 21.16, 14.94.

HRMS (ESI) m/z $[M + H]^+$ calculated for $C_{17}H_{20}NO_5PS$: 382.0873, found 382.0873.




ethyl hydrogen (4-methyl-1-(phenylsulfonyl)indolin-2-yl)phosphonate (90):

1H NMR (500 MHz, $CDCl_3$) δ 7.67 – 7.48 (m, 2H), 7.44 – 7.36 (m, 1H), 7.32 (d, $J = 8.0$ Hz, 1H), 7.26 (t, $J = 7.9$ Hz, 2H), 7.02 (t, $J = 7.8$ Hz, 1H), 6.75 (d, $J = 7.6$ Hz, 1H), 5.53 (dd, $J = 6.1, 1.2$ Hz, 1H), 3.87 (dq, $J = 9.7, 7.1$ Hz, 1H), 3.58 (dq, $J = 9.7, 7.0$ Hz, 1H), 2.80 – 2.44 (m, 2H), 2.01 (s, 3H), 1.10 (t, $J = 7.0$ Hz, 3H).

^{13}C NMR (126 MHz, $CDCl_3$) δ 139.98, 139.02, 134.62, 133.10, 130.36, 129.01, 127.83, 126.98, 126.06, 114.79, 92.00, 63.33, 35.60, 18.80, 14.97.

HRMS (ESI) m/z $[M + H]^+$ calculated for $C_{17}H_{20}NO_5PS$: 382.0873, found 382.0871.




ethyl hydrogen (6-chloro-1-(phenylsulfonyl)indolin-2-yl)phosphonate (91):

1H NMR (500 MHz, $CDCl_3$) δ 7.86 – 7.65 (m, 2H), 7.60 (d, $J = 1.8$ Hz, 1H), 7.53 (t, $J = 7.5$ Hz, 1H), 7.41 (t, $J = 7.7$ Hz, 2H), 7.07 – 6.82 (m, 2H), 5.60 (dd, $J = 4.8, 2.5$ Hz, 1H), 3.94 (dq, $J = 9.7, 7.1$ Hz, 1H), 3.65 (dq, $J = 9.7, 7.0$ Hz, 1H), 2.96 – 2.60 (m, 2H), 1.18 (t, $J = 7.0$ Hz, 3H).

^{13}C NMR (126 MHz, $CDCl_3$) δ 141.61, 138.89, 133.50, 133.43, 130.21, 129.26, 126.96, 125.90, 125.12, 117.83, 92.69, 63.48, 36.33, 14.92.

HRMS (ESI) m/z $[M + H]^+$ calculated for $C_{16}H_{17}ClNO_5PS$: 402.0326, found 402.0325.




tert-butyl (tert-butoxycarbonyl)(9-(1-(phenylsulfonyl)indolin-2-yl)-9H-purin-6-yl)carbamate (92):

^1H NMR (500 MHz, CDCl_3) δ 8.81 (s, 1H), 8.08 (s, 1H), 7.74 (d, $J = 8.1$ Hz, 1H), 7.71 – 7.65 (m, 2H), 7.55 (t, $J = 7.5$ Hz, 1H), 7.40 (t, $J = 7.8$ Hz, 2H), 7.34 (td, $J = 7.7, 1.8$ Hz, 1H), 7.23 – 7.06 (m, 2H), 6.83 (dd, $J = 8.9, 2.5$ Hz, 1H), 3.53 (dd, $J = 17.3, 9.0$ Hz, 1H), 3.28 (dd, $J = 17.3, 2.5$ Hz, 1H), 1.46 (s, 20H).

^{13}C NMR (126 MHz, CDCl_3) δ 152.39, 152.33, 150.63, 150.60, 142.39, 140.46, 137.51, 134.07, 129.54, 128.99, 128.92, 128.33, 126.97, 125.57, 125.54, 115.76, 83.98, 70.80, 37.25, 27.93.

HRMS (ESI) m/z $[\text{M} + \text{H}]^+$ calculated for $\text{C}_{29}\text{H}_{32}\text{N}_6\text{O}_6\text{S}$: 593.2177, found 593.2176.




tert-butyl (2-(2-(1H-pyrazol-1-yl)-1-tosylindolin-3-yl)ethyl)carbamate (93):

^1H NMR (500 MHz, CDCl_3) δ 7.63 (dd, $J = 19.8, 8.0$ Hz, 3H), 7.53 (d, $J = 1.7$ Hz, 1H), 7.45 – 7.35 (m, 2H), 7.32 – 7.24 (m, 3H), 7.21 (t, $J = 7.5$ Hz, 1H), 6.86 (d, $J = 7.9$ Hz, 1H), 6.26 (d, $J = 2.2$ Hz, 1H), 4.90 (s, 0H), 3.73 (p, $J = 4.4$ Hz, 1H), 3.30 (dt, $J = 14.5, 7.2$ Hz, 1H), 3.19 (dt, $J = 13.8, 6.5$ Hz, 1H), 2.48 (s, 3H), 1.60 (s, 9H), 1.27 (ddt, $J = 15.7, 11.8, 6.1$ Hz, 1H).

^{13}C NMR (126 MHz, CDCl_3) δ 156.26, 144.50 (d, $J = 78.9$ Hz), 140.78 (d, $J = 9.7$ Hz), 139.86, 135.96, 132.61, 129.71, 129.16, 128.42, 126.95, 124.32, 123.69, 113.83, 106.10, 79.12 (d, $J = 87.2$ Hz), 60.49, 43.95, 38.89, 28.53, 27.56, 21.61.

HRMS (ESI) m/z $[\text{M} + \text{H}]^+$ calculated for $\text{C}_{29}\text{H}_{32}\text{N}_6\text{O}_6\text{S}$: 593.2177, found 593.2176.




4-((S)-2-((tert-butoxycarbonyl)amino)-3-methoxy-3-oxopropyl)phenyl (1-(1-(phenylsulfonyl)indolin-2-yl)-1H-pyrazole-4-carboxylate (94):

1-(1-

^1H NMR (500 MHz, CDCl_3) δ 8.47 (s, 1H), 8.15 (s, 1H), 7.81 (dd, $J = 22.5, 8.0$ Hz, 3H), 7.72 (t, $J = 7.4$ Hz, 1H), 7.62 – 7.53 (m, 2H), 7.52 – 7.41 (m, 1H), 7.40 – 7.17 (m, 6H), 6.90 – 6.62 (m, 1H), 5.19 (d, $J = 8.3$ Hz, 1H), 4.75 (d, $J = 7.2$ Hz, 1H), 3.88 (d, $J = 1.8$ Hz, 3H), 3.67 (d, $J = 17.0$ Hz, 1H), 3.58 (dd, $J = 17.2, 8.7$ Hz, 1H), 3.26 (dq, $J = 14.1, 8.0$ Hz, 2H), 1.59 (s, 9H).

^{13}C NMR (126 MHz, CDCl_3) δ 172.33, 160.91, 155.19, 149.50, 142.58, 140.27, 138.07, 133.82, 133.76, 132.88, 130.40, 129.40, 128.92, 128.61, 126.87, 125.37, 125.29, 121.86, 115.62, 114.68, 80.12, 54.46, 52.39, 37.80, 36.14, 28.40.

HRMS (ESI) m/z $[\text{M} + \text{H}]^+$ calculated for $\text{C}_{33}\text{H}_{34}\text{N}_4\text{O}_8\text{S}$: 647.2170, found 647.2168.




((3aR,6S,7aS)-8,8-dimethyl-2,2-dioxidotetrahydro-3H-3a,6-methanobenzo[c]isothiazol-1(4H)-yl)(1-(1-(phenylsulfonyl)indolin-2-yl)-1H-pyrazol-4-yl)methanone (95):

^1H NMR (500 MHz, CDCl_3) δ 8.30 (d, $J = 13.7$ Hz, 1H), 7.85 (d, $J = 23.3$ Hz, 1H), 7.55 – 7.49 (m, 1H), 7.49 – 7.44 (m, 1H), 7.39 (dt, $J = 21.7, 7.9$ Hz, 2H), 7.27 (dt, $J = 11.2, 7.8$ Hz, 2H), 7.18 – 7.12 (m, 1H), 7.07 (t, $J = 6.9$ Hz, 1H), 6.96 (td, $J = 7.5, 3.5$ Hz, 1H), 6.44 (ddd, $J = 13.8, 8.7, 2.4$ Hz, 1H), 4.02 (ddd, $J = 7.5, 4.6, 2.6$ Hz, 1H), 3.63 – 3.13 (m, 4H), 2.10 – 1.73 (m, 5H), 1.38 – 1.31 (m, 1H), 1.28 (q, $J = 3.8, 2.8$ Hz, 1H), 1.15 (d, $J = 21.1$ Hz, 3H), 0.89 (d, $J = 7.7$ Hz, 3H).

^{13}C NMR (126 MHz, CDCl_3) δ 161.38 (d, $J = 10.7$ Hz), 142.85 (d, $J = 26.1$ Hz), 140.38 (d, $J = 15.4$ Hz), 138.42 (d, $J = 4.6$ Hz), 133.59 (d, $J = 53.8$ Hz), 133.51, 129.22 (d, $J = 8.3$ Hz), 128.73 (d, $J = 45.0$ Hz), 128.24 (d, $J = 5.8$ Hz), 126.79 (d, $J = 10.6$ Hz), 125.00 (d, $J = 8.2$ Hz), 124.66 (d, $J = 19.4$ Hz), 117.06 (d, $J = 2.4$ Hz), 114.61 (d, $J = 28.3$ Hz), 75.81 (d, $J = 11.9$ Hz), 65.95 (d, $J = 15.3$ Hz), 53.56 (d, $J = 12.7$ Hz), 48.14 (d, $J = 3.6$ Hz), 47.81, 45.01 (d, $J = 4.6$ Hz), 38.47 (d, $J = 5.3$ Hz), 35.93 (d, $J = 44.7$ Hz), 33.08 (d, $J = 5.7$ Hz), 26.53, 21.14 (d, $J = 17.1$ Hz), 19.92 (d, $J = 2.3$ Hz).

HRMS (ESI) m/z $[\text{M} + \text{H}]^+$ calculated for $\text{C}_{28}\text{H}_{30}\text{N}_4\text{O}_5\text{S}_2$: 567.1730, found 567.1728.




((3aS,5S,5aR,8aR,8bS)-2,2,7,7-tetramethyltetrahydro-5H-bis([1,3]dioxolo)[4,5-b:4',5'-d]pyran-5-yl)methyl 1-(1-(phenylsulfonyl)indolin-2-yl)-1H-pyrazole-4-carboxylate (96):

^1H NMR (500 MHz, CDCl_3) δ 8.00 (t, $J = 2.5$ Hz, 1H), 7.71 (d, $J = 5.6$ Hz, 1H), 7.61 – 7.44 (m, 3H), 7.40 (t, $J = 7.4$ Hz, 1H), 7.31 – 7.22 (m, 2H), 7.20 – 7.11 (m, 1H), 7.04 (d, $J = 7.6$ Hz, 1H), 6.96 (t, $J = 7.6$ Hz, 1H), 6.35 (dt, $J = 5.6, 2.5$ Hz, 1H), 5.42 (d, $J = 4.8$ Hz, 1H), 4.51 (dd, $J = 7.8, 2.4$ Hz, 1H), 4.42 – 4.12 (m, 4H), 4.01 (dd, $J = 5.1, 2.6$ Hz, 1H), 3.30 (d, $J = 5.7$ Hz, 2H), 1.38 (d, $J = 8.3$ Hz, 3H), 1.34 (s, 3H), 1.22 (s, 3H), 1.20 (d, $J = 4.7$ Hz, 3H).

^{13}C NMR (126 MHz, CDCl_3) δ 162.49, 142.22 (d, $J = 2.7$ Hz), 139.31 (d, $J = 270.3$ Hz), 133.71, 132.43 (d, $J = 20.1$ Hz), 129.34, 128.68 (dd, $J = 42.1, 2.7$ Hz), 126.81 (d, $J = 3.0$ Hz), 125.20 (d, $J = 3.8$ Hz), 125.18 (d, $J = 18.0$ Hz), 115.39, 115.22 (d, $J = 11.5$ Hz), 109.36 (d, $J = 103.6$ Hz), 96.40, 76.13 (d, $J = 7.2$ Hz), 71.16, 70.71 (d, $J = 21.5$ Hz), 66.18 (d, $J = 8.4$ Hz), 63.43, 36.74, 36.16 (d, $J = 6.3$ Hz), 26.17 (d, $J = 1.9$ Hz), 26.08, 25.11, 24.58.

HRMS (ESI) m/z $[\text{M} + \text{H}]^+$ calculated for $\text{C}_{30}\text{H}_{33}\text{N}_3\text{O}_9\text{S}$: 612.2010, found 612.2009.




4-(1-(1-(phenylsulfonyl)indolin-2-yl)-1H-pyrazol-4-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridine (97):

^1H NMR (500 MHz, CDCl_3) δ 8.22 (d, $J = 4.9$ Hz, 1H), 8.06 (s, 1H), 7.83 (s, 1H), 7.56 (d, $J = 7.9$ Hz, 2H), 7.49 (d, $J = 8.1$ Hz, 1H), 7.39 (t, $J = 7.4$ Hz, 1H), 7.31 (d, $J = 3.7$ Hz, 1H), 7.26 (t, $J = 7.6$ Hz, 2H), 7.22 – 7.12 (m, 3H), 7.03 (t, $J = 7.3$ Hz, 2H), 6.66 – 6.48 (m, 2H), 5.62 (s, 2H), 3.55 (d, $J = 17.0$ Hz, 1H), 3.50 – 3.34 (m, 3H), 0.84 (t, $J = 8.2$ Hz, 2H), -0.14 (d, $J = 1.7$ Hz, 9H).

^{13}C NMR (126 MHz, CDCl_3) δ 148.99, 143.60, 140.52, 139.63, 138.63, 137.23, 136.27, 133.57, 132.73, 129.26, 128.45, 128.10, 126.83, 125.22, 124.96, 120.99, 117.59, 115.07, 113.91, 100.51, 76.01, 73.13, 66.33, 35.92, 17.90, -1.30.

HRMS (ESI) m/z $[\text{M} + \text{H}]^+$ calculated for $\text{C}_{30}\text{H}_{33}\text{N}_5\text{O}_3\text{SSi}$: 572.2146, found 572.2144.




trans-9-(phenylsulfonyl)-4,4a,9,9a-tetrahydropyrano[2,3-b]indol-2(3H)-one (99):



^1H NMR (500 MHz, CDCl_3) δ 8.27 – 7.85 (m, 2H), 7.59 – 7.50 (m, 1H), 7.47 (dd, $J = 8.6, 6.9$ Hz, 2H), 7.27 (d, $J = 8.1$ Hz, 1H), 7.19 (q, $J = 7.9, 7.4$ Hz, 1H), 7.08 (d, $J = 7.5$ Hz, 1H), 7.02 (t, $J = 7.5$ Hz, 1H), 6.54 (d, $J = 7.5$ Hz, 1H), 3.72 (d, $J = 6.0$ Hz, 1H), 2.63 – 2.24 (m, 2H), 2.21 – 2.07 (m, 2H).



^{13}C NMR (126 MHz, CDCl_3) δ 168.99, 140.68, 139.04, 133.74, 129.54, 129.31, 129.11, 127.96, 124.39, 123.96, 113.77, 91.55, 38.18, 26.97, 21.06.



HRMS (ESI) m/z $[M + H]^+$ calculated for $C_{17}H_{15}NO_4S$: 330.0795 found 330.0793.



5. Spectral Data



























































































































































































































































































































































































































































































6. Single crystal X-ray diffraction data of 30

Table S5 Crystal data and structure refinement for mo_220822Peng_0ma.

| | |
|------------------------------------|---|
| Identification code | mo_220822Peng_0ma |
| Empirical formula | C ₈ H ₉ BrN ₂ O ₂ |
| Formula weight | 245.08 |
| Temperature/K | 100 |
| Crystal system | orthorhombic |
| Space group | Pccn |
| a/Å | 13.2630(13) |
| b/Å | 24.954(2) |
| c/Å | 5.6399(5) |
| α/° | 90 |
| β/° | 90 |
| γ/° | 90 |
| Volume/Å ³ | 1866.6(3) |
| Z | 8 |
| ρ _{calc} /cm ³ | 1.744 |
| μ/mm ⁻¹ | 4.372 |
| F(000) | 976.0 |
| Crystal size/mm ³ | 0.4 × 0.2 × 0.12 |
| Radiation | MoKα (λ = 0.71073) |
| 2θ range for data collection/° | 3.264 to 52.766 |
| Index ranges | -16 ≤ h ≤ 15, -31 ≤ k ≤ 31, -7 ≤ l ≤ 6 |
| Reflections collected | 11450 |
| Independent reflections | 1899 [R _{int} = 0.0190, R _{sigma} = 0.0128] |

| | |
|--|----------------------------------|
| Data/restraints/parameters | 1899/0/119 |
| Goodness-of-fit on F^2 | 1.042 |
| Final R indexes [$I > 2\sigma(I)$] | $R_1 = 0.0185$, $wR_2 = 0.0462$ |
| Final R indexes [all data] | $R_1 = 0.0213$, $wR_2 = 0.0473$ |
| Largest diff. peak/hole / $e \text{ \AA}^{-3}$ | 0.42/-0.23 |

Molecular structure. There are 8 molecules per unit cell, 1 molecule per asymmetric unit. The thermal displacement ellipsoids are at a 50% probability level.



Unit cell and packing. View almost along axis c :




Table S6 Fractional Atomic Coordinates ($\times 10^4$) and Equivalent Isotropic Displacement Parameters ($\text{\AA}^2 \times 10^3$) for mo_220822Peng_0ma. U_{eq} is defined as 1/3 of the trace of the orthogonalised U_{ij} tensor.

| Atom | x | y | z | U(eq) |
|------|------------|-----------|------------|----------|
| Br1 | 3598.4(2) | 7001.0(2) | -1184.7(3) | 17.81(7) |
| O1 | 3838.3(9) | 3244.7(5) | 5371(2) | 18.6(2) |
| O2 | 3437.3(8) | 4006.0(5) | 7275(2) | 19.7(3) |
| N1 | 3707.8(9) | 5511.8(6) | 1510(2) | 14.4(3) |
| N2 | 3891.7(10) | 5782.8(6) | 3556(2) | 16.3(3) |
| C4 | 3953.1(11) | 4643.0(6) | 3285(3) | 15.3(3) |
| C3 | 3985.8(12) | 4041.9(6) | 3180(3) | 15.7(3) |
| C6 | 3576.9(11) | 5844.0(7) | -372(3) | 14.4(3) |
| C7 | 3682.3(11) | 6353.9(6) | 503(3) | 14.3(3) |
| C5 | 3699.6(11) | 4942.5(7) | 1461(3) | 15.6(3) |
| C2 | 3712.9(11) | 3781.5(7) | 5508(3) | 14.4(3) |
| C8 | 3872.1(12) | 6297.8(7) | 2930(3) | 16.3(3) |
| C1 | 3687.8(13) | 2962.1(7) | 7582(3) | 23.3(4) |

Table S7 Anisotropic Displacement Parameters ($\text{\AA}^2 \times 10^3$) for mo_220822Peng_0ma. The Anisotropic displacement factor exponent takes the form: $-2\pi^2[h^2a^*U_{11}+2hka^*b^*U_{12}+\dots]$.

| Atom | U ₁₁ | U ₂₂ | U ₃₃ | U ₂₃ | U ₁₃ | U ₁₂ |
|------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| Br1 | 25.59(11) | 12.92(10) | 14.92(11) | 0.28(6) | -0.75(6) | 1.71(6) |
| O1 | 25.8(6) | 13.8(6) | 16.3(6) | 0.2(5) | 2.7(5) | -1.4(5) |
| O2 | 26.1(6) | 16.9(6) | 16.2(6) | -2.5(5) | 3.5(5) | 0.7(5) |

Table S7 Anisotropic Displacement Parameters ($\text{\AA}^2 \times 10^3$) for mo_220822Peng_0ma. The Anisotropic displacement factor exponent takes the form: $-2\pi^2[h^2a^*U_{11}+2hka^*b^*U_{12}+\dots]$.

| Atom | U ₁₁ | U ₂₂ | U ₃₃ | U ₂₃ | U ₁₃ | U ₁₂ |
|------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| N1 | 16.2(6) | 15.4(7) | 11.7(6) | -1.9(5) | -0.6(5) | 0.0(5) |
| N2 | 20.0(6) | 17.1(7) | 11.8(6) | -1.9(5) | -2.9(5) | 0.5(5) |
| C4 | 15.3(7) | 15.2(8) | 15.5(8) | -2.3(6) | -0.6(6) | -1.1(6) |
| C3 | 16.2(7) | 16.6(8) | 14.3(8) | -0.9(7) | 0.5(6) | 0.8(6) |
| C6 | 15.3(7) | 16.7(8) | 11.3(7) | -1.1(6) | -1.1(6) | 1.0(6) |
| C7 | 14.8(7) | 14.1(8) | 14.0(7) | 1.3(6) | 0.7(6) | 2.5(6) |
| C5 | 16.6(7) | 14.8(8) | 15.2(8) | -3.4(6) | -0.3(6) | -0.5(6) |
| C2 | 12.0(7) | 13.3(8) | 17.9(8) | -0.3(7) | -2.3(6) | -1.2(6) |
| C8 | 17.8(7) | 17.0(8) | 14.3(8) | -4.1(7) | -1.8(6) | 1.2(6) |
| C1 | 31.3(10) | 16.4(9) | 22.2(10) | 5.2(7) | 1.3(7) | -2.5(7) |

Table S8 Bond Lengths for mo_220822Peng_0ma.

| Atom | Atom | Length/ \AA | Atom | Atom | Length/ \AA |
|------|------|----------------------|------|------|----------------------|
| Br1 | C7 | 1.8778(16) | N2 | C8 | 1.333(2) |
| O1 | C2 | 1.3519(19) | C4 | C3 | 1.502(2) |
| O1 | C1 | 1.446(2) | C4 | C5 | 1.315(2) |
| O2 | C2 | 1.200(2) | C3 | C2 | 1.509(2) |
| N1 | N2 | 1.3597(18) | C6 | C7 | 1.372(2) |
| N1 | C6 | 1.358(2) | C7 | C8 | 1.399(2) |
| N1 | C5 | 1.421(2) | | | |

Table S9 Bond Angles for mo_220822Peng_0ma.

| Atom | Atom | Atom | Angle/° | Atom | Atom | Atom | Angle/° |
|------|------|------|------------|------|------|------|------------|
| C2 | O1 | C1 | 114.65(13) | C6 | C7 | Br1 | 127.53(13) |
| N2 | N1 | C5 | 121.00(13) | C6 | C7 | C8 | 106.11(15) |
| C6 | N1 | N2 | 112.50(13) | C8 | C7 | Br1 | 126.36(13) |
| C6 | N1 | C5 | 126.46(14) | C4 | C5 | N1 | 123.44(15) |
| C8 | N2 | N1 | 104.56(13) | O1 | C2 | C3 | 110.35(14) |
| C5 | C4 | C3 | 122.98(15) | O2 | C2 | O1 | 123.17(16) |
| C4 | C3 | C2 | 112.90(14) | O2 | C2 | C3 | 126.47(15) |
| N1 | C6 | C7 | 105.79(14) | N2 | C8 | C7 | 111.05(15) |

Table S10 Torsion Angles for mo_220822Peng_0ma.

| A | B | C | D | Angle/° | A | B | C | D | Angle/° |
|-----|----|----|-----|-------------|----|----|----|----|-------------|
| Br1 | C7 | C8 | N2 | -179.38(11) | C6 | N1 | N2 | C8 | 0.16(17) |
| N1 | N2 | C8 | C7 | -0.30(18) | C6 | N1 | C5 | C4 | 171.33(15) |
| N1 | C6 | C7 | Br1 | 179.49(10) | C6 | C7 | C8 | N2 | 0.33(18) |
| N1 | C6 | C7 | C8 | -0.21(16) | C5 | N1 | N2 | C8 | 178.12(13) |
| N2 | N1 | C6 | C7 | 0.04(17) | C5 | N1 | C6 | C7 | -177.78(13) |
| N2 | N1 | C5 | C4 | -6.3(2) | C5 | C4 | C3 | C2 | -147.55(15) |
| C4 | C3 | C2 | O1 | -174.75(12) | C1 | O1 | C2 | O2 | -4.5(2) |
| C4 | C3 | C2 | O2 | 4.1(2) | C1 | O1 | C2 | C3 | 174.43(12) |
| C3 | C4 | C5 | N1 | -177.21(14) | | | | | |

Table S11 Hydrogen Atom Coordinates ($\text{\AA}\times 10^4$) and Isotropic Displacement Parameters ($\text{\AA}^2\times 10^3$) for mo_220822Peng_0ma.

| Atom | x | y | z | U(eq) |
|------|---------|---------|----------|-------|
| H4 | 4123.15 | 4814.67 | 4733.85 | 18 |
| H3B | 4672.79 | 3927.27 | 2717.42 | 19 |
| H3A | 3512.87 | 3916.29 | 1941.22 | 19 |
| H6 | 3440.66 | 5743.99 | -1965.36 | 17 |
| H5 | 3500.64 | 4769.14 | 36.01 | 19 |
| H8 | 3973.65 | 6588.3 | 3992.5 | 20 |
| H1A | 3828.1 | 2580.13 | 7350.71 | 35 |
| H1B | 2988.51 | 3007.98 | 8105.37 | 35 |
| H1C | 4144.83 | 3106.83 | 8788.03 | 35 |

Experimental

The single crystal XRD of $\text{C}_8\text{H}_9\text{BrN}_2\text{O}_2$ [mo_220822Peng_0ma] was studied on a 'Bruker Kappa APEX-II' diffractometer. The crystal was kept at 100.0 K during data collection. Using the Olex2 [1] environment, the structure was solved with the ShelXT [2] structure solution program using Intrinsic Phasing and refined with the ShelXL [3] refinement package using Least Squares minimization.

1. Dolomanov, O.V., Bourhis, L.J., Gildea, R.J, Howard, J.A.K. & Puschmann, H. (2009), *J. Appl. Cryst.* 42, 339-341.
2. Sheldrick, G.M. (2015). *Acta Cryst.* A71, 3-8.
3. Sheldrick, G.M. (2015). *Acta Cryst.* C71, 3-8.

Crystal structure determination of [mo_220822Peng_0ma]

Crystal Data for $\text{C}_8\text{H}_9\text{BrN}_2\text{O}_2$ ($M=245.08$ g/mol): orthorhombic, space group Pccn (no. 56), $a = 13.2630(13)$ \AA , $b = 24.954(2)$ \AA , $c = 5.6399(5)$ \AA , $V = 1866.6(3)$ \AA^3 , $Z = 8$, $T = 100$ K, $\mu(\text{MoK}\alpha) = 4.372$ mm^{-1} , $D_{\text{calc}} = 1.744$ g/cm^3 , 11450 reflections measured ($3.264^\circ \leq 2\Theta \leq 52.766^\circ$), 1899 unique ($R_{\text{int}} = 0.0190$, $R_{\text{sigma}} = 0.0128$) which were used in all calculations. The final R_1 was 0.0185 ($I > 2\sigma(I)$) and wR_2 was 0.0473 (all data).

Refinement model description

Number of restraints - 0, number of constraints - unknown.

Details:

1. Fixed Uiso

At 1.2 times of:

All C(H) groups, All C(H,H) groups

At 1.5 times of:

All C(H,H,H) groups

2.a Secondary CH₂ refined with riding coordinates:

C3(H3B,H3A)

2.b Aromatic/amide H refined with riding coordinates:

C4(H4), C6(H6), C5(H5), C8(H8)

2.c Idealised Me refined as rotating group:

C1(H1A,H1B,H1C)

References:

APEX2 (data collection)

Bruker (2007). *APEX2*. Bruker AXS Inc., Madison, Wisconsin, USA.

SAINT (integration and reduction)

Bruker (2007). *SAINT*. Bruker AXS Inc., Madison, Wisconsin, USA.

SADABS (absorption correction)

Sheldrick, G. M. (1996). SADABS. University of Göttingen, Germany.

SHELXTL (structure solution and refinement)

Sheldrick, G. M. (2008). *Acta Cryst.* **A64**, 112–122.

PLATON

Spek, A. L. (2003). *J. Appl. Cryst.* **36**, 7–13.

OLEX2

Dolomanov, O.V., Bourhis, L.J., Gildea, R.J., Howard, J.A.K., Puschmann H. (2008), *J. Appl. Cryst.* **42**, 339-341.